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ABSTRACT 
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer, and 
metastasis is a leading cause of mortality in these patients.  Fibulin-3, a secreted extracellular 
matrix protein, has a pro-invasive role in other cancers.  However, a role for fibulin-3 in 
TNBC invasion is unknown. We have previously shown that KISS1R signaling promotes 
TNBC cell invasion through EGFR and MMP-9 activity, via β-arrestin2.  Thus, we 
hypothesized that KISS1R signaling promotes TNBC cell invasion via fibulin-3.  Our clinical 
data suggests that plasma fibulin-3 levels are elevated in metastatic TNBC patients.  
Additionally, we found that invasive breast cancer cells have increased expression of fibulin-
3 and treatment with kisspeptin, the KISS1R ligand, further increased fibulin-3 expression 
and secretion.  Also, depletion of β-arrestins in TNBC cells decreased fibulin-3 expression.  
Furthermore, fibulin-3 depletion in TNBC cells inhibited cell invasiveness through decreased 
MMP-9 activity.  These results identify fibulin-3 as a new signaling partner of KISS1R and 
as a potential anti-metastasis target in TNBC. 
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1.1 Breast Cancer  
Breast cancer is the most common cancer diagnosed in Canadian women over the age 
of 20 and it is estimated that approximately 1 in 9 women will develop breast cancer in her 
lifetime
†
.  In 2015, it is estimated that 25 000 Canadian women will be diagnosed with breast 
cancer
†
.  Additionally, breast cancer is the second leading cause of cancer deaths in Canadian 
women with approximately 5 000 deaths estimated for 2015, representing 14% of all cancer 
deaths
†
.  It is evident that breast cancer is a very prevalent disease with devastating 
consequences, and therefore it is imperative that the molecular processes of breast cancer 
development and progression be better understood so that early diagnostics and clinical 
therapies can be further advanced. 
1.1.1 Breast Cancer Staging 
Breast cancer staging is a means of determining the extent to which the cancer has 
developed and spread to other tissues in the body [1].   Clinically, breast cancer staging is 
utilized by physicians to estimate patient prognosis, since patient 10 year survival decreases 
with increasing cancer stage [2].  The tumor-node-metastasis (TNM) staging system is the 
clinical standard that takes into account the size of the primary tumor (T), the extent of 
lymph node involvement (N), and the presence of metastases in distant tissues (M) [1].  
Breast cancer commonly develops from the epithelium that lines the ducts or lobules of the 
mammary glands and is defined as ductal carcinoma in situ (DCIS) or lobular carcinoma in 
situ (LCIS).   At this point, the cancer would be classified as stage 0, since the tumor has not 
invaded into the surrounding tissue and remains confined by the basement membrane to the 
ducts or lobules of the breast.  However, as the cancer progresses these abnormal epithelial 
cells will undergo further molecular alterations promoting their survival and invasion into the 
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surrounding tissue [3].  Thus, the aforementioned cancers become known as invasive ductal 
carcinoma (IDC) and invasive lobular carcinoma (ILC). These cancers would be within the 
range of stage I – III, which are classified based on the size of the primary tumor and the 
extent that breast cancer cells have spread to lymph nodes in close proximity to the breast 
(Figure 1.1).  The final stage, stage IV, involves breast cancer that has metastasized to 
distant tissues, such as the bone, lung, liver and brain [4].   
1.1.2 Breast Cancer Classification: Hormone Receptor Status 
Although the TNM staging system is an important tool in predicting patient 
prognosis, a limitation of the system is that it only takes into account tumor burden and 
excludes tumor biology [5].  It has been suggested that biomarkers and hormone receptor 
status should be included in the staging system of breast cancer to assist clinicians in 
optimizing treatments and to better predict survival [5].  Specifically, triple negative breast 
cancer (TNBC), which represents 15-20% of all breast cancer cases, consists of tumor cells 
that lack the estrogen receptor (ER), progesterone receptor (PR), and human epidermal 
growth factor receptor (HER)2 [6].  Consequently, this breast cancer subtype does not 
effectively respond to established hormone or HER2-targeted therapies.  TNBC patients have 
poorer prognosis, a high recurrence rate, and decreased survival compared to other breast 
cancer subtypes [7,8,9].  TNBC patients are often younger than 50 years of age, African 
American, and are more likely to have BRCA1 mutations [10,11,12,13].  Moreover, 
approximately 60% of TNBC patients display overexpression of the epidermal growth factor 
receptor (EGFR) [14].   
EGFR (HER1), is a member of the EGF receptor family of receptor tyrosine kinases, 
which also comprises HER2, HER3 and HER4.  This receptor family regulates a number of 
4 
 
important cellular functions such as cell proliferation, survival and cell motility [15].  
Activation of these receptors involves ligand binding, which induces homo- or 
heterodimerization of EGFR with another receptor of the family, most frequently HER2 [15].  
This dimerization promotes the autophosphorylation of the intracellular tyrosine residues, 
thereby allowing for interactions with intracellular signaling effectors and the initiation of 
signaling cascades [16].  Additionally, dysregulated expression and activity of EGFR has 
been demonstrated to promote tumorigenesis and metastasis in several cancers, including 
breast cancer [15].    
Heitz and colleagues reported that women with TNBC displayed a higher rate and 
earlier occurrence of cerebral metastases compared to ER-positive patients [17].  Currently, 
chemotherapy is the only available pharmacological treatment used to treat TNBC; however, 
due to the aggressive nature and genomic instability of the tumors, TNBC patients develop 
chemoresistance [18].  Therefore, it is important that targeted therapies be further 
investigated and developed for use in TNBC patients.  Recently, the purportedly normal cells 
of the tumor microenvironment have emerged as potential targets due to their ability to 
regulate the growth and function of the tumor itself [19]. 
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Figure 1.1.  Breast cancer staging.  Stage I- III are classified based on the size of the 
primary tumor and presence of cancer in regional lymph nodes.  Stage I involves a tumor less 
than 2 cm in size and no lymph node involvement.  Typically, stage II is a primary tumor of 
2-5 cm in size and presence of cancer cells in the lymph nodes surrounding the breast.  Stage 
III is a primary tumor greater than 5 cm in addition to regional lymph node involvement.   
Lastly, stage IV involves distant metastases in other tissues of the body such as the brain, 
lungs, liver and bone.  Adapted from the website of the National Cancer Institute 
(http://www.cancer.gov). 
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1.2 Breast Cancer Metastasis 
Metastasis is the process by which cancer cells detach from the primary tumor and 
travel mainly through the blood stream or lymphatic system to distant parts of the body [21].  
When breast cancer remains confined to the breast and does not undergo metastasis, 5-year 
survival rates exceed 90% [22].  However, breast cancer patient prognosis is adversely 
affected by the extent and site of metastases [23].   
1.2.1 Metastatic Cascade 
The metastatic cascade comprises a series of complex steps (Figure 1.2), the first step 
in breast carcinoma development begins with cellular transformation of non-malignant 
epithelial cells to a malignant phenotype, which has been suggested to be a result of acquired 
genetic instability [24].  Cellular transformation involves uncontrolled growth regulation and 
increased cell survival, due to evasion of apoptotic signaling [25].   
Initial separation and spreading of cancer cells from the primary tumor involves a 
process known as epithelial-to-mesenchymal transition (EMT), where cells lose expression 
of epithelial markers and gain expression of mesenchymal markers, introducing a more 
migratory and invasive phenotype [26].  Normally, epithelial cells are tightly organized in 
continuous sheets of polarized cells, forming a barrier that is necessary to maintain 
homeostasis and protect the body.  Epithelial cells display an apical-basolateral polarity, with 
distinct expression profiles at each plasma membrane [27].  Cell-cell adhesion and 
communication is accomplished through the use of gap and tight junctions, desmosomes, and 
adherens junctions [27].    However, during EMT cells lose polarity and cell-cell attachment 
due to the loss of important adhesion molecules, such as E-cadherin [28].  At the same time, 
cells also acquire a mesenchymal phenotype through increased expression of mesenchymal 
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markers, including N-cadherin, vimentin and matrix metalloproteases (MMPs) [29].  Cells 
which have undergone EMT are capable of migrating away from the primary site through 
cell-matrix interactions and cytoskeletal reorganization [30]. 
In addition to migration, cancer cells must invade through the basement membrane 
that borders the tumor and into the surrounding extracellular matrix (ECM)(Figure 1.2) [31].  
Thus, ECM remodeling must occur to allow cancer cell migration and invasion through the 
tissue.  This is accomplished by several proteolytic enzymes that are produced and secreted 
by cancer cells [28].  The most common proteases involved in cancer metastasis are 
urokinase-type plasminogen activators (uPA), cathepsins and MMPs [32,33,34].  Secretion 
and activation of these proteolytic enzymes results in uncontrolled degradation of the 
basement membrane and surrounding ECM, presenting the cancer cells with an avenue for 
migration and metastasis.  Additionally, the degradation of the ECM releases growth factors, 
such as epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF), 
which can subsequently act on cancer cells to further promote angiogenesis and metastatic 
progression [35].   
The next step in the metastatic cascade is angiogenesis, the process by which new 
blood vessels are formed from pre-existing vessels (Figure 1.2) [25].  Angiogenesis occurs 
in normal physiological conditions, such as wound healing, the menstrual cycle and 
placentation during pregnancy [36].  The process of angiogenesis is carefully controlled by a 
balance of pro- and anti-angiogenic factors.  However, in cancer, this balance is disrupted 
and angiogenesis-inducing factors are abundantly released from tumor cells and the 
surrounding stromal cells [36].  As the primary tumor continues to grow in size its need for 
oxygen and nutrients exceeds what the present vessels can sufficiently deliver and hypoxic 
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conditions are introduced.  Hypoxia increases factors such as hypoxia inducible factor -1 
(HIF-1), which has been shown to be increased in invasive breast carcinoma compared to in 
situ tumors [37].  HIF-1 stimulates the release of pro-angiogenic factors, such as VEGF, from 
tumor cells and from the degradation of the ECM [38].  VEGF subsequently binds to VEGF 
receptors on endothelial cells of pre-existing vessels in the surrounding tissue, stimulating the 
proliferation of endothelial cells and the development of a new vessel network within the 
tumor itself and the surrounding tissue [37].  Furthermore, VEGF expression has been 
inversely correlated to breast cancer patient survival [39].  Due to incomplete formation, 
these new blood vessels have abnormal architecture and consequently there is increased 
fenestration, enhancing the permeability and likelihood that cancer cells will enter the 
circulation [36].   
Once the tumor cells have invaded through the epithelial basement membrane and 
surrounding ECM they will reach the newly formed tumor-associated vasculature.  The 
tumor cells must then transverse the endothelial cell basement membrane to reach the 
vascular endothelial cells.  It has been reported that blood vessel-associated macrophages 
produce chemoattractants, such as EGF, to attract breast cancer cells to the vessel [40].  The 
next step in the metastatic cascade is intravasation, the process by which these cancer cells 
will enter the vessels through leaky endothelial cell junctions (Figure 1.2) [41].  Initially, 
cancer cells adhere to endothelial cells, and then through endothelial cell retraction and 
cancer cell migration, the cancer cell enters the vasculature by transendothelial migration 
[41].  Additionally, cancer cells may also enter the circulation via the lymphatic system.  In 
contrast to the cardiovascular system, cells of the lymphatic system lack tight intracellular 
junctions, and therefore lymph node metastases are more common earlier in tumor 
progression and generally indicate poor prognosis [36].  Cancer cells that survive in the 
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circulation arrive in capillary beds in distant tissues, adhere to endothelial cells, and enter the 
surrounding tissue by extravasation (Figure 1.2) [42].  Many of the metastasized cells 
undergo apoptosis, however a subset of metastasized cells may survive and enter dormancy 
or proliferation [43].  Like the primary tumor, the secondary tumor also requires 
angiogenesis to occur to supply the growing tumor with oxygen and nutrients.   
Paget’s century-old “seed and soil” theory proposes that the interaction between the 
cancer cells or “seeds” and the organ microenvironment or “soil” explains the preference for 
metastatic cells for certain organs [44].  This theory suggests that metastasis is multifactorial 
and that the processes are influenced by factors independent from the tumor cell itself [44].   
Additionally, it has been suggested that the organ microenvironment at the site of metastasis 
can distinctly modify the gene-expression profile of cancer cells and consequently alter their 
behaviour and growth [43].   Therefore, it is imperative that the tumor microenvironment and 
its potential effects on the development of aggressive tumors be further investigated.  
Specifically, new therapeutic strategies targeting the molecular changes that occur in regards 
to expression of cell-cell and cell-ECM adhesion molecules and cell signaling cascades are 
worth considering for the development of anti-metastatic drugs [19]. 
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Figure 1.2.  The metastatic cascade.  The process of metastasis, when cancer cells spread 
from a primary tumor to distant tissues, requires several processes to occur.  Initially, tumor 
cells undergo proliferation to form a primary tumor mass (i).  As the tumor progresses, some 
tumor cells will exit their primary sites of growth and enter the surrounding tissue through 
invasion and migration (ii).  Next, to supply the growing tumor with oxygen and nutrients, 
new blood vessels are formed through a process known as angiogenesis (iii).  Some cancer 
cells will enter the newly formed blood vessels via intravasation (iv) and survive in the 
circulation (v).  At distant tissues, cancer cells will exit the circulation through extravasation 
(vi) and undergo metastatic colonization (vii).  Adapted from Valastyan & Weinberg (2011) 
[45]. 
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1.3 Tumor Microenvironment 
 The tumor microenvironment consists of the ECM, soluble factors and altered cell 
types, including fibroblasts, endothelial cells and leukocytes [46].  These cells can interact 
directly or through paracrine signaling with surrounding cells [47].  Like any organ, the 
development and function of a tumor is the result of unique communication between 
epithelial cells and surrounding stromal cells [47].  Evidence suggests that disruptions to the 
ECM composition and structure may pave the way for tumor development or lead to cancer-
causing mutations [48].  In addition to degrading the normal ECM, stromal cells of the 
microenvironment, primarily cancer-associated fibroblasts (CAFs), will deposit a new tumor-
associated ECM that consists of molecules such as fibronectin, tenascins and stiffer collagen 
that will facilitate tumor cell motility [49].  Furthermore, studies have demonstrated that the 
gene expression profile of the tumor-associated ECM is dramatically altered, including 
upregulation of MMPs in invasive stroma compared to in situ stroma [50].  Additionally, due 
to their altered signaling pathways, cancer cells may fail to interpret cues from the 
microenvironment, and this can result in inappropriate cellular organization and growth [48]. 
For example, in three-dimensional (3D) culture, mammary epithelial cells will form 
polarized acini-like structures, but malignant cells in 3D culture form disorganized colonies 
[51].  These malignant cells will revert to organized polarized structures when cell-ECM β1 
integrin signaling is inhibited [51].  Therefore, the influence of the tumor microenvironment, 
especially cell-cell and cell-ECM interactions, has become an emerging target for therapeutic 
strategies. 
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1.3.1 Fibulins 
 The fibulin family consists of seven secreted glycoproteins associated with basement 
membranes, elastic fibers and the ECM [52].  The fibulin family name is derived from the 
Latin word fibula meaning clasp or buckle.  It is fitting then, that fibulins function as 
intramolecular bridges within ECM components, such as elastic fibres and basement 
membranes [53].  Interestingly, the fibulins are highly conserved in species as evolutionarily 
diverse as worms and humans [53].  Structural features of the fibulins include repeated EGF-
like domains and a unique C-terminal fibulin-type module (Figure 1.3), and these proteins 
have been implicated in cell signaling and protein-protein interactions involved in cell 
growth, adhesion and motility [54].  The physiological and pathological roles of many of the 
fibulins have been extensively studied, however only within the last decade have roles for 
fibulin-3 been discovered  [54]. 
1.3.2 Fibulin-3 
 Fibulin-3, also known as EGF-containing fibulin-like extracellular matrix protein 1 
(EFEMP1), interacts with tropoelastin and plays an important role in elastic fibre assembly 
during development [52].  Fibulin-3 is strongly expressed in human heart and placenta and 
weakly expressed in skeletal muscle, lung, brain and pancreas [55].  Fibulin-3 was also 
shown to be expressed in the bone and cartilage of murine embryos, suggesting that fibulin-3 
may play a role in skeletal development [56].  Additionally, fibulin-3 is highly expressed in 
epithelial and endothelial cells [55].  The fibulin-3 promoter contains Sp1 transcription factor 
binding sites, in addition to an estrogen response element, and estrogen has been shown to 
supress fibulin-3 transcription in retinal cells [57].  Similarly, estrogen stimulation of ERα-
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positive MCF7 breast cancer cells repressed the expression of the gene for fibulin-3, referred 
to as EFEMP1 [58].   
 The  physiological roles of fibulin-3 in development and disease have been elucidated 
by studying animal knockout models and heritable human disorders [54].  The phenotype of 
the fibulin-3 knockout mouse involves reduced reproductivity, early aging, herniation and 
lack of support for pelvic organs [59,60].  These observations are likely a result of reduced 
elastic fibers in the fascia, a thin layer of connective tissue that separates and protects the 
body’s organs [59].  Furthermore, a missense mutation in an EGF domain of fibulin-3 has 
been discovered as the cause of early-onset macular degenerative diseases including Malattia 
Leventinese and Doyne’s honeycomb retinal dystrophy [61].  These inherited macular 
degenerative diseases resemble the most common cause of incurable blindness, age-related 
macular degeneration, and are characterized by yellow-white deposits of ECM, called drusen, 
that accumulate between Bruch’s membrane and the retinal pigment epithelium [52].  
Interestingly, mutations in tissue inhibitor of metalloproteinases-3 (TIMP-3), an inhibitor of 
MMPs, are also associated with macular degenerative diseases, and TIMP-3 has been shown 
to bind fibulin-3 [62].  Lastly, fibulin-3 has been described as an indirect regulator of cell 
growth through indirect protein interactions with the tumor suppressor differential screening-
selected gene aberrative in neuroblastoma (DAN) [63].  Fibulin-3 has also been shown to 
promote cell proliferation by stimulating deoxyribonucleic acid (DNA) synthesis in vitro 
through autocrine or paracrine signaling [64].  
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Figure 1.3. Structure of the fibulins. The fibulins contain a collection of epidermal growth 
factor (EGF)-like motifs and a C-terminal fibulin-type module, unique to the fibulins and 
fibrillins.  Additionally, the N-terminal domains differ between the fibulin family members.  
Adapted from de Vega et al. (2009) [52]. 
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1.3.3 Fibulin-3 in Cancer 
 In the last five years, several studies have shown that fibulin-3 plays a role in 
tumorigenesis.  Fibulin-3 is differentially expressed in human cancers, and its effects have 
been described as both tumor suppressive and oncogenic (Table 1.1) [65].  Fibulin-3 
expression is decreased in colorectal [66], lung [67], prostate [68], nasopharyngeal [69] and 
hepatocellular carcinomas [65].  In lung cancer, fibulin-3 downregulation promotes invasion 
and metastasis through activation of Wnt/β -catenin signaling and MMP-7 [70].  Similarly,  
Xu and colleagues showed that fibulin-3 negatively regulated lung cancer cell invasiveness 
via p38-mitogen-activated protein kinase (MAPK) and MMP-2 and -9 [71].  In 
nasopharyngeal carcinoma, fibulin-3 was shown to inhibit cell migration and invasion 
through suppression of AKT phosphorylation [69].  In a fibulin-3 overexpression model in 
pancreatic cancer cells, cancer stem cell markers were decreased, cells were resensitized to 
cytotoxic agents and EMT was inhibited [72].  Thus, numerous studies have demonstrated 
that fibulin-3 can have tumor suppressive roles in various human cancers. 
 Conversely, fibulin-3 has been reported to be upregulated in pancreatic [73], 
ovarian[74] and cervical [75] carcinomas, as well as malignant gliomas [76] and malignant 
mesothelioma [77].  Plasma and effusion fibulin-3 levels were reported to be increased in 
patients with pleural mesothelioma compared to patients without pleural mesothelioma, and 
therefore fibulin-3 has been proposed as a clinical biomarker for the disease [78].  
Interestingly, fibulin-3 has also been shown to bind cell surface receptors, specifically EGFR 
in pancreatic carcinoma cells (Figure 1.4) [79].  Camaj and colleagues demonstrated that 
fibulin-3 competes with EGF for binding to EGFR, and activates downstream extracellular 
signal-regulated kinase (ERK1/2) and AKT signaling cascades involved in cancer cell 
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growth [79].  Fibulin-3 has pro-angiogenic roles in pancreatic [73] and ovarian [74] 
carcinomas and malignant gliomas [80].  Fibulin-3 was upregulated in human ovarian 
carcinoma tissues and positively correlated with microvessel density (MVD) and VEGF 
expression [74].  Serum fibulin-3 levels were also elevated in ovarian carcinoma patients 
compared to healthy controls and benign ovarian carcinoma patients, and were associated 
with low differentiation, high stage and lymph node metastasis [74].  Pancreatic cancer cells 
transfected with fibulin-3 displayed increased MVD, tumor growth and VEGF production in 
vivo [73].  Additionally, tumor cells that were transfected with fibulin-3 displayed a decrease 
in apoptosis and a shift from G0-G1 phase to S phase and mitosis, implicating fibulin-3 in 
tumor cell survival and cell cycle progression [73].  Similar results were observed in an in 
vivo model of malignant glioma in regards to VEGF secretion and MVD, and fibulin-3 was 
found to be localized around tumor blood vessels [80].  Also, fibulin-3 stimulated endothelial 
cell migration via a Notch-dependent signaling mechanism, a proliferative pathway 
dysregulated in many cancers [80].  Malignant glioma cells and tumors overexpressing 
fibulin-3 displayed increased expression and activity of MMP-2 and 9 [76].  Fibulin-3 has 
also been shown to promote glioma cell survival and invasion through activation of Notch 
signaling [81].  In contrast to Tong and colleagues, who suggested decreased fibulin-3 is 
associated with poor prognosis in colorectal cancer, a recent study reports that fibulin-3 
promotes colorectal cancer cell migration and invasion and tumor growth via a p38 MAPK 
mechanism [82]. 
 Although a role for fibulin-3 in breast cancer invasion is unknown, fibulin-3 has been 
reported to be overexpressed in breast cancer effusions [83].  However, whether fibulin-3 
signaling regulates TNBC cell migration and invasion, important processes required for 
metastasis, is currently unknown and will be investigated in this study.   
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Table 1.1: Role of fibulin-3 in various cancers. 
Cancer Evidence Ref 
Tumor Suppressive 
Colorectal  ↓ fibulin-3 protein in clinical tissue correlated with increased 
tumor stage, lymph node metastasis and poor survival. 
[66] 
Lung  Promoter methylation in cancer cell lines and clinical tissue. 
 Fibulin-3 decreases invasion and metastasis in vivo by 
supressing Wnt/beta-catenin signaling and inhibition of 
MMP-7. 
 Overexpression of fibulin-3 inhibits cell growth, migration 
and invasion and decreased the expression and activity of 
MMP-2/9. 
[67] 
[70] 
[71] 
Prostate  Promoter methylation in cell lines and clinical tissue. [68] 
Nasopharyngeal  ↓ fibulin-3 mRNA and protein in clinical tissue correlated 
with tumor progression, lymph node metastasis and poor 
survival. 
 Fibulin-3 decreases cell migration and invasion through 
decreased pAKT activity. 
[69] 
Hepatocellular  ↓ fibulin-3 mRNA and protein in cell lines and clinical 
tissue, correlated with poor survival. 
 Fibulin-3 knockdown increased cancer cell viability and 
invasion. 
[65] 
Oncogenic 
Pancreatic  ↑ fibulin-3 mRNA in metastatic cancer cells and clinical 
tumor samples and overexpression results in enhanced tumor 
growth in vivo, and rescues tumor cells from apoptosis. 
 Fibulin-3 competitively binds and activates EGFR, leading 
to phosphorylation of AKT and ERK1/2. 
[73] 
[79] 
Ovarian  ↑ fibulin-3 serum levels associated with high stage, low 
differentiation, lymph node metastasis and poor prognosis. 
 ↑ fibulin-3 mRNA and protein in clinical tissue positively 
correlated with MVD and VEGF expression. 
[74] 
Cervical  Fibulin-3 protein expression was positively correlated with 
MVD and VEGF mRNA, and overexpression was associated 
with lymph node metastasis, vascular invasion and poor 
survival. 
[75] 
Malignant 
glioma 
 ↑ fibulin-3 mRNA and protein in cell lines and clinical tissue 
and overexpression of fibulin-3 increases expression and 
activity of MMP-2/9 and tumor dispersion in vivo.  
 Overexpression of fibulin-3 increased tumor VEGF levels, 
MVD, and vessel permeability. 
 Fibulin-3 promotes tumor cell survival and invasion through 
activation of Notch signaling. 
[76] 
[80] 
[81] 
Malignant 
mesothelioma 
 ↑ fibulin-3 plasma and effusion levels. [78] 
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Figure 1.4. Fibulin-3 activates EGFR in pancreatic cancer.  Camaj and colleagues 
demonstrated that fibulin-3 competes with epidermal growth factor (EGF) for binding to 
epidermal growth factor receptor (EGFR) in pancreatic carcinoma cells, resulting in 
autophosphorylation of EGFR. Additionally, downstream cell growth signaling cascades are 
activated through phosphorylation of AKT and extracellular signal-regulated kinase 
(ERK1/2) [79]. 
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1.4 Matrix Metalloproteinases 
 MMPs are a family of zinc-dependent endopeptidases that are capable of degrading 
other proteinases, proteinase inhibitors, cell surface receptors, cell-cell adhesion molecules 
and essentially all ECM proteins [84].  Thus, since tumor cells must cross multiple ECM 
barriers to metastasize to distant sites, and upregulation of MMPs is associated with invasive 
ability in many cancers, MMPs can promote metastasis [85].  Additionally, a role for MMPs 
has been demonstrated in EMT, angiogenesis and intravasation [86,87,88].    
1.4.1 Matrix Metalloproteinase-9 in Cancer 
 MMP-9 is secreted as an inactive pro-MMP that can be activated by plasmin, trypsin-
2, MMP-2, MMP-13 and MMP-3 [89].  There are numerous substrates for MMP-9, a few of 
which include collagens, elastin, plasminogen and kisspeptins [90].  MMP-9 is primarily 
produced and secreted by stromal cells, however cancer cells may stimulate stromal cell 
production through paracrine signaling [34].  Increased MMP-9 expression and activity has 
been demonstrated in many cancers, including brain, urogenital, lung, skin, colorectal and 
breast [91].  Data from transgenic mice expressing an MMP-9 promoter-driven β-
galactosidase transgene demonstrate that the MMP-9 promoter activity is induced during 
invasive cancer, but not in situ tumors [92].  MMP-9 has also been proposed as a prognostic 
biomarker in breast cancer due to its significant association with aggressive subtypes of 
breast cancer, such as TNBC, and its correlation with metastasis and relapse [93].  It has been 
demonstrated that MMP-9 regulates cell invasion downstream of ERK signaling in glioma 
[94] and breast cancer (ERα-positive MCF7 and TNBC MDA-MB-231) cells [95].  
Moreover, it has been reported that EGF stimulates MMP-9 expression and activity in an 
ERK-dependent manner in ERα-negative SKBR3 breast cancer cells [96].  
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 Despite its role in invasion, MMP-9 does more than just degrade ECM components, 
MMP-9 can also regulate signaling pathways such as proliferation, survival and angiogenesis 
[90].  The hemopexin (PEX) domain of both, inactive and active MMP-9 allows it to dock to 
the hyaluronan receptor CD44 and initiate intracellular signaling cascades (Figure 1.5) [97].  
Thus, in normal keratinocytes and malignant cells, proteolytically active MMP-9 binds to 
CD44 on the cell surface and cleaves latent transforming growth factor-β (TGF-β) into an 
active form, allowing it to activate its receptor and lead to enhanced tumor growth [97].   
Catalytically inactive MMP-9 has been shown to increase leukemia cell survival after 
docking to integrin and CD44 and activating intracellular anti-apoptosis pathways [98].  Both 
active and pro-MMP-9 have been implicated in breast cancer cell migration through 
interaction with CD44 [99,100].   Bourguignon and colleagues showed that CD44 is closely 
associated with active MMP-9 in invadopodia, actin-rich protrusions of the plasma 
membrane that are associated with degradation of the ECM [99].  Similarly, Dufour and 
colleagues demonstrated that pro-MMP-9 interacts with CD44 on tumor epithelial cells, 
leading to EGFR activation and phosphorylation of downstream signaling molecules, such as 
ERK, AKT, and focal adhesion kinase (FAK) to increase cell migration [100].  MMP-9 has 
also been shown to induce angiogenesis in pancreatic islet cells by stimulating VEGF release, 
and MMP inhibitors and MMP-9 knockout decreased the number of angiogenic islets and 
tumor burden [101].  MMP-9 has also been implicated in the process of intravasation, since 
MMP inhibition significantly reduced intravasation and only cancer cells expressing MMP-9 
intravasated [88]. 
 Thus, due to the ability of MMPs to facilitate invasion and metastasis, inhibitors have 
been developed to target their proteolytic activity in the hopes of preventing metastasis.  
Unfortunately, these therapies have failed clinically, and it has been suggested that it may be 
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a result of their lack of selectivity towards MMPs [90].  However, our knowledge of MMPs 
has grown considerably, particularly in regards to their non-proteolytic abilities, interactions 
with cell surface proteins and resulting downstream signaling cascades.  New 
pharmacological inhibitors are focusing on blocking the PEX domain from binding to cell 
surface proteins and therefore preventing subsequent effects on cell survival, migration and 
angiogenesis [102].  This strategy has already been used to target MMP-9 [89,100].  
Synthetic peptides that bind specific sites within the MMP-9 PEX domain were shown to 
inhibit cell motility in both human fibrosarcoma and breast cancer cell lines [100].  Similarly, 
a small inhibitor that prevents PEX from binding to cell surface integrins decreases cell 
migration and tumor growth [103].  These studies suggest that pharmacologically targeting 
the PEX domain of MMP-9 may be clinically beneficial alone or in combination with other 
therapeutics to effectively prevent tumor growth and metastasis. 
 MMP-9 serum levels have been shown to be high in breast cancer compared to 
benign breast disease and healthy controls [104].  Additionally, high MMP-9 serum levels 
were associated with lymph node metastasis, increased tumor stage, and lower overall 
survival [104].  Interestingly, fibulin-3 has been shown to regulate the expression and activity 
of MMP-9 in malignant glioma, however the role of fibulin-3 in regulating MMP-9 in breast 
cancer remains unknown and will be investigated by the current study.   
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Figure 1.5.  Signaling cascades induced by pro-MMP-9 interaction with cell surface 
proteins.  (A) Pro-matrix metalloproteinase (MMP)-9 interacts with α4β1 integrin and CD44 
via its hemopexin (PEX) domain to activate Lyn, phosphorylate signal transducer and 
activator of transcription 3 (STAT3) and upregulate the anti-apoptosis protein MCl-1 in 
chronic lymphocytic leukemia cells.  (B) Similarly, the PEX domain of pro-MMP-9 
facilitates binding to CD44 on tumor epithelial cells (COS-1 kidney cells, HT1080 
fibrosarcoma cells and MDA-MB-435 melanoma cells) resulting in the activation of 
epidermal growth factor receptor (EGFR) and the phosphorylation of intracellular signaling 
molecules extracellular signal-regulated kinase (ERK), AKT and focal adhesion kinase 
(FAK) that stimulate cell migration.  Adapted from Bauvois (2012) [90]. 
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1.5 Metastasis Suppressor Genes 
Recently, new groups of genes have been classified as metastasis activator or 
metastasis suppressor genes.  These genes differ from oncogenes and tumor suppressor genes 
in that they do not influence primary tumor growth, but rather are involved in metastasis of 
cancer cells to distant tissues [105].  Metastasis requires cancer cells to undergo a series of 
processes to successfully colonize secondary sites, therefore a gene that inhibits even one of 
these processes would effectively block metastasis [106].  There have been over 150 genes 
discovered to be involved in breast cancer tumor development and progression, however only 
6 metastasis suppressor genes have been shown to function in vivo, in metastasis assays [22].  
These include NME1, KAI1, BRMS1, MKK4, E-cadherin and KISS1 [22].  Evidently, 
metastasis suppressor genes provide a promising target for pharmacological interventions to 
prevent metastasis in cancer patients. 
1.5.1 KISS1R Signaling 
 The metastasis suppressor gene, KISS1, encodes a 145-residue kisspeptin protein that 
is rapidly cleaved into shorter secreted peptides termed kisspeptin-10 (KP-10), kisspeptin-13, 
kisspeptin-14 and kisspeptin-54 (Figure 1.6A) [107].  The shorter kisspeptins are N-
terminally truncated peptides of kisspeptin-145 cleaved by furin, MMP-2, -9, and -14 or 
prohormone convertases [108].  KP-10 is the shortest biologically active kisspeptin, and is 
highly conserved among vertebrates [109].  Kisspeptins are the endogenous ligand for the 
kisspeptin receptor (KISS1R) [107,110,111].  KISS1R has a single high affinity binding site 
for kisspeptins, and all kisspeptins bind with similar affinities and potencies 
[107,110,112,113].  KISS1 and KISS1R expression have been shown in similar tissues, 
24 
 
including the placenta, pituitary, pancreas, brain, small intestine, liver, lung, kidney, testis, 
ovary and breast [107,110,111].   
 KISS1R is a G-protein coupled receptor (GPCR) that signals via a Gq/11-coupled 
mechanism leading to activation of phospholipase C (PLC) (Figure 1.6B).  PLC activation 
leads to increased production of inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) 
which results in increased intracellular calcium and subsequent activation of protein kinase C 
(PKC) and ERK1/2 [107,110,111].  In addition, KISS1R has been shown to activate ERK1/2 
through a G-protein independent and β-arrestin2-dependent pathway [114].  KISS1R 
contains residues in the second intracellular loop and cytoplasmic tail that allow it to 
constitutively interact with β-arrestin1 and β-arrestin2 [115].  Also, desensitization and 
internalization of KISS1R is mediated by G-protein-coupled receptor serine/threonine kinase 
2 (GRK2) and β-arrestins [116].  Bianco and colleagues observed persistent expression of 
KISS1R at the plasma membrane, even after KP-10 stimulation, and there was no co-
localization of KISS1R with lysosomal markers, indicating that ligand-induced KISS1R 
internalization does not result in lysosomal degradation [117].  Instead, KISS1R is recycled 
to the cell surface, prolonging KISS1R signaling, and suggesting that KISS1R may have 
constitutive activity [117]. 
KP/KISS1R signaling plays an important physiological role in the regulation of the 
reproductive axis and the initiation of puberty [118].  Studies have shown that loss-of-
function mutations in KISS1R result in hypogonadotropic hypogonadism in humans [116]. 
Hypogonadotropic hypogonadism is characterized by diminished functional activity of the 
gonads and infertility due to the insufficiency of the pituitary to secrete gonadotropins: 
follicle-stimulating hormone (FSH) and luteinizing hormone (LH) [116].   KP/KISS1R 
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signaling regulates the reproductive axis by stimulating the release of gonadotropin-releasing 
hormone (GnRH) [118].   Pulsatile GnRH secretion then stimulates the pituitary to synthesize 
and secrete FSH and LH [119].  KP/KISS1R signaling has also been implicated in pregnancy 
and placentation.  The circulating serum levels of KP increase approximately 1000 fold in the 
first trimester and an amazing 10,000 fold in the third trimester, signifying an important role 
for KP throughout pregnancy [120].  Moreover, KP has been shown to inhibit trophoblast 
migration and invasion through decreased MMP-2 [121].  Consequently, KP has been 
proposed to play a critical role in regulating placental invasion of the uterine wall during 
implantation [121].  Due to the emergence of KISS1R as a clinically relevant GPCR, it is 
vital that the molecular pathways regulating KISS1R signaling be further investigated in 
other diseases and conditions.  
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Figure 1.6. Kisspeptins (KP) and KISS1R signaling cascades. (A) Cleavage of kisspeptin-
145 results in the production of smaller peptides, termed KP-54, KP-14, KP-13 and KP-10. 
(B) The kisspeptin receptor (KISS1R) is a Gq/11-coupled receptor that upon binding of its 
ligand, KP, will activate phospholipase C (PLC) and extracellular signal-regulated kinase 
(ERK1/2).  Activation of PLC will lead to production of diacylglycerol (DAG) and increased 
intracellular calcium which will result in activation of protein kinase C (PKC).  Additionally, 
KISS1R can also signal independently of G-proteins to activate ERK1/2 in a β-arrestin2 
dependent mechanism. 
 
A 
B 
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1.5.2 KISS1R Signaling in Cancer 
 The KP/KISS1R system functions as a metastasis suppressor in melanoma [105], 
pancreatic [122], bladder [123], ovarian [124], endometrial [124], esophageal [125], lung 
[126] and gastric cancers [127].  These cancers displayed decreased expression of KISS1 and 
/or KISS1R in tumor tissue compared to non-malignant tissue, and this observation correlated 
with decreased patient prognosis.  KISS1 signaling was first studied in melanoma and was 
found to be expressed in non-metastatic cells, but was absent in metastatic melanoma cell 
lines [105].  KISS1 mRNA expression was also lower in pancreatic carcinoma tissue in 
comparison to non-malignant tissue [122].  When stimulated with exogenous KP, pancreatic 
cancer cells exhibited ERK1 activation and decreased migration, however no effect on cell 
proliferation was observed [122].  In gastric cancer, KP-145 protein expression was reduced 
in metastatic tissues from the lymph nodes and liver compared to the primary tumor [127].  
In bladder [123] and ovarian [128] carcinomas, decreased expression of KISS1 mRNA was 
associated with poor patient survival.  In a fibrosarcoma cell line, exogenous expression of 
KISS1 resulted in decreased MMP-9 expression and activity, as well as reduced invasion 
[129].  The observed decrease in MMP-9 expression was attributed to diminished nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFκB) transcription factor binding to 
the promoter of MMP-9 as a result of KISS1 expression [129].  Thus, KISS1R undeniably 
plays a role in metastasis and may serve as a potential therapeutic target in cancer. 
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1.5.3 KISS1R Signaling in Breast Cancer 
 In contrast to its role as a metastasis suppressor in numerous cancers, KP/KISS1R 
signaling has been shown to play detrimental roles in breast cancer.  The first study looked at 
clinical KISS1 and KISS1R mRNA expression in breast tumor tissue and discovered that 
KISS1 expression was elevated in breast cancer tissue compared to non-malignant mammary 
tissue [130].  However, this study did not examine hormone receptor status.  Additionally, 
breast tumors positive for lymph node metastasis displayed increased KISS1 mRNA 
compared to lymph node negative tumors [130].  However, no significant difference in 
KISS1R mRNA expression was observed [130].  Exogenous expression of KISS1 in the 
human breast cancer cell line MDA-MB-231 enhanced motility, invasive ability and reduced 
cell adhesion, therefore KISS1 overexpression induced a more aggressive phenotype [130].  
Lastly, this study demonstrated the positive correlation between KISS1 mRNA expression 
and poor patient prognosis [130].   
 The second study examined ERα status and KISS1 expression in breast tumors.  
Marot and colleagues demonstrated that ERα-positive breast tumors expressed sevenfold less 
KISS1 than ERα-negative breast tumors [131].  This study showed that treatment of ERα-
positive MCF7 and T47D breast cancer cells with the estrogen receptor antagonist, 
tamoxifen, stimulated KISS1 and KISS1R mRNA expression [131].  Exogenous expression of 
ERα in the ERα-negative breast cancer cell line MDA-MB-231 resulted in diminished KISS1 
mRNA expression [131].  Similarly, ERα-positive breast tumors in postmenopausal women 
treated with tamoxifen also displayed high KISS1 and KISS1R mRNA levels that was 
associated with shorter relapse-free survival [131].  Furthermore, KISS1 mRNA expression in 
breast tumors was shown to increase with grade [131].  The results of this study suggest that 
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KISS1 and KISS1R mRNA levels in breast tumors may be a prognostic marker for anti-
estrogen therapy resistance [131].  Therefore clinical data suggests that KP/KISS1R signaling 
may play an influential role in breast cancer progression. 
 A 2011 study investigated a role for mouse KP/KISS1R signaling in regulating breast 
cancer metastasis.  Breast cancer was induced in mice expressing the polyoma middle T 
antigen (PyMT) under the control of the mouse mammary tumor virus (MMTV) promoter to 
explore the role of KISS1R expression in breast cancer progression and metastasis [132].  
Results from this study indicated that PyMT-induced breast tumor development and lung 
metastases were delayed in the KISS1R heterozygous (PyMT/Kiss1r
+/−
) mouse in 
comparison to the wild-type (PyMT/Kiss1r
+/+
) mouse [132].  Interestingly, KISS1R 
heterozygous (PyMT/Kiss1r
+/−
) tumors displayed a significant reduction in MMP-9 mRNA 
compared to wild-type (PyMT/Kiss1r
+/+
) tumors [132].  Furthermore, heterozygous mouse 
primary breast cancer cells exhibited decreased cellular invasion in vitro [132].  Accordingly, 
this study proposes that KP/KISS1R signaling regulates breast tumor development, 
progression and metastasis in a mouse model. 
 Studies from our laboratory have investigated the underlying molecular mechanisms 
regulated by KP/KISS1R in breast cancer metastasis (Figure 1.7) [133,134].  Our first study 
demonstrated that treatment of human TNBC cell lines, MDA-MB-231 and Hs578T, with 
KP-10, stimulated migration and invasion [133].  Interestingly, KP-10 stimulation also 
increased MMP-9 secretion and activity [133].  We found that activation of KISS1R 
signaling promoted the activation of EGFR via a β-arrestin2 dependent pathway [133].  
Lastly, fluorescence resonance energy transfer (FRET) analysis determined that KISS1R 
directly associates with EGFR under basal conditions and KP-10 treatment enhanced this 
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interaction [133].  In our second study, we found that exogenous KISS1R expression or KP-
10 treatment induced EMT and cell invasion in ERα-negative non-malignant mammary 
epithelial MCF10A cells [134].  This demonstrates that KP signaling stimulates malignant 
transformation.  KISS1R overexpression in ERα-negative SKBR3 breast cancer cells 
stimulated extravasation in vivo using the chick chorioallantoic membrane assay [134].  Most 
interestingly, KP-10 failed to stimulate invasion and EGFR activation in ERα-positive MCF7 
and T47D breast cancer cells, leading us to conclude that ERα negatively regulates KISS1R 
signaling in breast cancer [134].  This concept was validated by exogenously expressing ERα 
in the ERα-negative MDA-MB-231 breast cancer cells, and upon estradiol stimulation KP-
10-induced invasion and EGFR activation was blocked, and KISS1R protein expression was 
decreased [134].  This demonstrates that ERα negatively regulates KISS1R expression and 
signaling.  Finally, we discovered that KISS1R tranactivation of EGFR is dependent upon an 
actin cytoskeletal binding protein, IQ-motif-containing GTPase activating protein 1 
(IQGAP1), and that IQGAP1 is a novel binding partner of KISS1R [134].  However, the 
molecular mechanism by which KP/KISS1R signaling stimulates TNBC cell invasion is still 
largely unknown and will be further investigated by this thesis. 
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Figure 1.7. KISS1R signaling in ERα-negative breast cancer.  Kisspeptin receptor 
(KISS1R) signaling induces epithelial-to-mesenchymal transition (EMT).  Also, KISS1R 
activation leads to anchorage independent growth and cytoskeletal reorganization through the 
small GTPase, RhoA.  Kisspeptin binds and activates KISS1R leading to epidermal growth 
factor receptor (EGFR) activation via β-arrestin2 and IQGAP1 dependent pathways.  
Additionally, β-arrestin2 is required for kisspeptin stimulated matrix metalloproteinase 
(MMP)-9 activity and breast cancer cell invasion.  Estrogen receptor (ER)α negatively 
regulates KISS1R expression and signaling in breast cancer cells.  Adapted from Cvetkovic et 
al. (2013) [134]. 
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1.5.4 β-arrestins 
 β-arrestins are ubiquitously expressed  proteins that function as signaling adaptors 
and molecular scaffolds [135], and play a crucial role in the phosphorylation of intracellular 
targets.  The two β-arrestin isoforms (β-arrestin1 and β-arrestin2) display a high degree of 
homology (~70% of similar sequence identity) and may function similarly to regulate GPCR 
desensitization and internalization [136].  β-arrestins can also regulate the signaling and 
trafficking of other types of receptors, such as EGFR  and the TGF-β receptor [137].  β-
arrestins are capable of scaffolding numerous cell signaling molecules, including many that 
have oncogenic roles and regulate the cytoskeleton, such as proto-oncogene tyrosine-protein 
kinase Src (Src), ERK1/2 and AKT [138].   
β-arrestins are also emerging regulators of breast cancer progression and metastasis.  
β-arrestin1 was shown to regulate phosphorylation of ERK1/2 in ERα-positive MCF7 breast 
cancer cells, and β-arrestin1 depletion resulted in decreased tumor cell proliferation [139].  β-
arrestin1 has also been shown to promote survival of breast cancer cells in hypoxic 
conditions via increased expression of VEGF and positively regulate breast cancer metastatic 
spread in nude mice [136].  Furthermore, depletion of both β-arrestin1 and β-arrestin2 in 
MDA-MB-231 breast cancer cells decreased tumor growth and increased mouse survival rate 
in experimental metastasis assays [136].  Another breast cancer study has linked amplified 
stromal β-arrestin1 expression with poor patient prognosis and increases in HIF-1 expression, 
tumor growth and metastases [140].  Clinical data from our lab has shown that the expression 
of β-arrestin2 is elevated in invasive human breast cancer, and that β-arrestin2 regulates the 
invasion of ERα-negative breast cancer cells, upon binding to small GTPases, Ral and 
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Rap1A [141,142].  Lastly, we have shown that KP-10-induced EGFR transactivation and cell 
invasion is dependent on β-arrestin2 [133]. 
1.6 Rationale, Hypothesis and Objectives 
1.6.1 Rationale 
 Fibulin-3 is overexpressed in breast cancer effusions [83], however, whether plasma 
fibulin-3 concentrations change in TNBC patients is currently unknown.  Despite evidence 
that fibulin-3 is capable of binding and activating EGFR [79], as well as upregulating MMP-
9 [76], a role for fibulin-3 in TNBC cell invasion has not yet been determined. Previous 
studies from our lab have demonstrated that in TNBC cells, KISS1R signaling stimulates cell 
invasion by stimulating EGFR activation and MMP-9 secretion and activity [133,134].  Here 
we will investigate whether fibulin-3 regulates KISS1R-induced TNBC cell invasion and the 
underlying mechanism(s). 
1.6.2 Hypothesis 
 KISS1R stimulates TNBC cell invasion via a fibulin-3 dependent mechanism.  
1.6.3 Objectives 
To determine if: 
1) Plasma fibulin-3 levels are increased in TNBC patients compared to healthy 
controls. 
2) Fibulin-3 regulates KISS1R-induced TNBC cell invasion, and uncover the 
potential underlying mechanism(s). 
3) Fibulin-3 regulates EGFR phosphorylation in TNBC cells.  
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2.1 cBioPortal Data Mining 
cBioPortal for Cancer Genomics (www.cbioportal.org), a publicly available online 
data portal to search and analyze cancer genomics data sets was used to investigate the genes 
of interest, EFEMP1 and KISS1. The Breast Invasive Carcinoma (TCGA, Provisional) data 
set (n=962) was used for all data mining [1,2].  
 
2.2 Blood Collection and Fibulin-3 ELISA 
The study was approved by the Western's Research Ethics Boards, and all participants 
provided informed consent.  Blood (5 mL) was collected in BD Vacutainer K2 EDTA tubes 
(VWR International; Radnor, PA, USA) from healthy patients, non-metastatic TNBC 
patients or metastatic TNBC patients presenting at The Breast Care Program of St. Joseph’s 
Health Care London.  Blood was centrifuged at 3000 rpm for 10 min, and the plasma was 
collected and frozen immediately in liquid nitrogen.  Samples were stored at -80 °C and 
subsequently thawed to quantify plasma fibulin-3 concentrations using an enzyme-linked 
immunosorbent assay (ELISA) kit (USCN Life Science Inc.; Wuhan, Hubei, China) 
according to manufacturer’s instructions [3].  Absorbance was measured at 450 nm using a 
Victor 3V Multi-Detection Microplate Reader (PerkinElmer; Waltham, MA, USA).   
 
2.3 Cell Culture  
Human breast cell lines were purchased from American Type Culture Collection 
(Manassas, VA, USA) and were maintained at 37 °C with 5% CO2 (Table 2.2).  The cell 
lines differ in invasiveness and ERα expression.  MCF10A cells were cultured in Mammary 
Epithelial Basal Medium supplemented with a MEGM Single Quots kit (bovine pituitary 
extract, human epidermal growth factor, insulin, hydrocortisone, gentamicin/amphotericin) 
46 
 
(Clonetics-Cambrex; Walkersville, MD, USA) and cholera toxin (100 ng/mL).  MCF7 cells 
were grown in DMEM (Invitrogen; Carlsbad, CA, USA) supplemented with 10% (vol/vol) 
fetal bovine serum (FBS) (Sigma-Aldrich; St. Louis, MO, USA) and 0.3% insulin. SKBR3, 
Hs578T and MDA-MB-231 cells were cultured in Roswell Park Memorial Institute (RPMI) 
1640 (Invitrogen; Carlsbad, CA, USA) supplemented with 10% (vol/vol) FBS.   
 
2.4 Stable Transfections and Gene Knockdown 
The weakly invasive SKBR3 breast cancer cells express very low levels of KISS1R 
[4], and therefore a gain-of-function model was generated by stably expressing FLAG-
KISS1R or pFLAG (vector control) constructs, as previously described [4].  FLAG-KISS1R 
or pFLAG (vector control) constructs were also stably expressed in the mammary epithelial 
cell line MCF10A, as previously described [4].  Cells (1 x 10
6
) were transfected by 
microporation (1700 V, 10 pulse width, 3#) using the Neon™ Transfection System 
(Invitrogen; Carlsbad, CA, USA) according to the manufacturer’s instructions.  
Heterogeneous populations of stable transfectants were selected using medium containing 
Geneticin (1.5 µg/mL).  Overexpression of KISS1R was verified by Western blot analysis. 
Gene knockdown of β-arrestin1 and β-arrestin2 in MDA-MB-231 cells has been 
previously described [5,6].  Cells (5 x 10
6
) were transfected with gene specific small hairpin 
ribonucleic acid (shRNA) (OriGene Technologies; Rockville, MD, USA) by electroporation 
(Gene Pulser Xcell, Bio-Rad; Hercules, CA, USA) according to the instructions of the 
manufacturer (250 V, 950 μF).  Gene knockdown of fibulin-3 was achieved using lentivirus-
delivered pGFP-C-shLenti shRNA Cloning Plasmid (Origene Technologies; Rockville, MD, 
USA).  Heterogeneous populations of stable transfectants were selected using medium 
containing puromycin (1.5 µg/mL).  Cells expressing scrambled controls were also 
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generated.  Knockdown of fibulin-3, β-arrestin1 and β-arrestin2 was verified by Western blot 
analysis. 
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Table 2.2. Human cell models used in the study. 
 Human Mammary Epithelial Cells Characteristics 
MCF10A: non-malignant mammary 
epithelial 
 
 FLAG-KISS1R 
Non-invasive [7] 
ERα negative [8] 
 
Highly invasive [4] 
Human Breast Cancer Cells  
MCF7 Non- invasive [9] 
ERα positive [10] 
SKBR3  
 
 
 FLAG-KISS1R  
Weakly invasive [11] 
ERα negative [11] 
 
Highly invasive [4] 
Hs578T  
 
 
 Fibulin-3 shRNA #1  
 Fibulin-3 shRNA #2  
 
Invasive [12] 
ERα negative [12] 
 
MDA-MB-231 
 
 
 β-arrestin1 shRNA  
 β-arrestin2 shRNA  
 
 Fibulin-3 shRNA #1  
 Fibulin-3 shRNA #2 
Highly invasive [13] 
ERα negative [13] 
 
Reduced invasion [5] 
Reduced invasion [5] 
   
Note: all generated cell lines are stable cell lines. 
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2.5 Immunoblot Assays 
Cells were treated with KP-10 (100 nM) (Phoenix Pharmaceuticals; Burlingame, CA, 
USA) as determined by previous dose response studies [4,14], in FBS supplemented media 
for 72 hours, where applicable.  Cells were washed with ice-cold phosphate-buffered saline 
(PBS), lysed with RIPA lysis buffer (150 mM NaCl, 50 mM Tris pH 8, 5 mM EDTA, 1% 
NP40, 0.1% SDS, 10 mM NaF, 0.5% deoxycholate, 10 mM sodium pyrophosphate, protease 
inhibitors: 1 µL/mL aprotinin, 1 µL/mL leupeptin and 10 µL/mL AEBSF) and centrifuged at 
14,000 rpm at 4 °C for 20 minutes.  Protein (50 µg) was separated by SDS-PAGE and 
transferred to nitrocellulose, followed by blocking in 10% skim milk and incubation with 
primary antibody in 3% skim milk overnight at 4 °C.  Protein expression was studied using 
the following primary antibodies: mouse anti-β-arrestin1 (1:300; BD Transduction 
Laboratories; San Jose, CA, USA), mouse anti-β-arrestin2 (1:1000; Abcam; Cambridge, 
UK), rabbit anti-fibulin-3 (1:1000; Abcam; Cambridge, UK), rabbit anti-KISS1R (1:2000, 
Abcam, Cambridge, UK), rabbit anti-MMP-9 (1:500; Abcam; Cambridge, UK), rabbit anti-
ERK1/2 (1:1000; Cell Signaling; Beverly, MA, USA), rabbit anti-phoshpo-ERK1/2 (1:2000; 
Cell Signaling; Beverly, MA, USA), rabbit anti-AKT (1:1000; Cell Signaling; Beverly, MA, 
USA), rabbit anti-phospho-AKT (1:1000; Cell Signaling; Beverly, MA, USA).  β-Actin or 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression was used as a loading 
control and was examined with a rabbit anti-Actin (1:2000; Sigma-Aldrich; St. Louis, MO, 
USA), mouse anti-Actin (1:2000; GeneTex Inc.; Irvine, CA, USA) or rabbit anti-GAPDH 
(1:5000; GeneTex Inc.; Irvine, CA, USA).  After 1 hour incubation with horseradish 
peroxidase (HRP)-conjugated secondary antibodies, rabbit (1:2500, GE Healthcare; 
Buckinghamshire, UK) or mouse (1:2500, GE Healthcare; Buckinghamshire, UK) the 
proteins were visualized using SuperSignal West Dura Chemiluminescent Substrate (Thermo 
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Scientific; Waltham, MA, USA) and a VersaDoc Imaging System (Bio-Rad; Hercules, CA, 
USA). 
 
2.6 Immunofluorescence Microscopy 
Immunostaining was performed as previously described [4,6,14].  Breast cells were 
washed with Hank’s Balanced Salt Solution (HBSS), fixed and permeabilized with 4% 
paraformaldehyde and 0.2% Triton-X (room temperature, 20 min), followed by blocking in 
3% bovine serum albumin in HBSS for 30 minutes.  The primary antibody fibulin-3 (rabbit 
1:50; Abcam; Cambridge, UK) was incubated for 1 hour.  After washing in HBSS, cells were 
incubated with the secondary antibody anti-rabbit AlexaFluor 488.  Nuclei were stained with 
0.01% Hoechst 33258 (Invitrogen; Carlsbad, CA, USA) for 5 minutes, and then washed 5 
times with cold HBSS.  Two replicates were conducted for each condition and images were 
acquired by confocal microscopy using an LSM-510 META laser-scanning microscope 
(Zeiss; Jena, Germany).   
 
2.7 Immunoblot Assays for Fibulin-3 Secretion 
 MDA-MB-231 and Hs578T cells (3 x 10
6
) expressing fibulin-3 shRNA or scrambled 
controls were plated in a 10 cm culture dish, serum starved for 24 hours and then the 
conditioned media was collected.  SKBR3 pFLAG and FLAG-KISS1R cells (3 x 10
6
) were 
also plated in 10 cm culture dishes, serum starved for 24 hours and then stimulated with 100 
nM KP-10 for 24 hours, following stimulation, conditioned media were collected.  
Conditioned media were concentrated using Microsep™ 10K Advance Centrifugal Filters 
(Pall® Life Sciences; Port Washington, NY, USA) and centrifuged at 5000 rcf at 4 °C for 30 
minutes.  Protein (75 µl) was separated by SDS-PAGE and transferred to nitrocellulose, 
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followed by blocking in 10% skim milk and incubation with rabbit anti-fibulin-3 (1:1000; 
Abcam; Cambridge, UK) primary antibody in 3% skim milk overnight at 4 °C.  After 1 hour 
incubation with HRP-conjugated secondary antibody, the proteins were visualized using 
SuperSignal West Dura Chemiluminescent Substrate (Thermo Scientific; Waltham, MA, 
USA) and a VersaDoc Imaging System (Bio-Rad; Hercules, CA, USA). 
 
2.8 Scratch Assays for Motility  
MDA-MB-231 and Hs578T cells expressing fibulin-3 shRNA or scrambled control were 
plated in duplicate and grown to 100% confluence in a 12-well plate, serum starved for 24 
hours and subsequently scratched with a sterile pipette tip, as described previously [4,14].  
Cells in FBS supplemented media were allowed to migrate into the scratch for 18 hours and 
were imaged every 15 minutes using an automated Olympus IX-81 microscope (Olympus; 
Shinjuku, Tokyo, Japan).  Distance travelled was measured and analyzed using InVivo 
Analyzer Suite (Media Cybernetics; Rockville, MD, USA).  For each image taken (per time 
point), the width of the scratch (μm) was measured at seven points along the scratch.  The 
distance migrated was calculated by subtracting the width of the scratch at each time point 
from the width of the scratch at time zero.  The distances migrated at each of the seven points 
along the scratch were averaged to determine the distance migrated for each well. 
 
2.9 Cell Migration and Invasion Assays 
Transwell chamber migration and Matrigel invasion assays were conducted as 
previously stated [4,14], with MDA-MB-231 and Hs578T cells depleted of fibulin-3 or 
scrambled control.  Transwell filters (8 μm pores) were placed into a 24-well plate containing 
either serum-free RPMI 1640 media or media supplemented with 10% FBS.  Cells (4 x 10
4
) 
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were plated in the upper chamber in either serum-free media or serum-free media 
supplemented with 100 nM KP-10 (Phoenix Pharmaceuticals; Burlingame, CA, USA) as 
determined by previous studies [4,14] and incubated for 20 hours.  For invasion assays, cells 
were layered on top of a 1 in 10 dilution of Matrigel (8.0 mg/mL; BD Biosciences; Franklin 
Lakes, NJ, USA) dissolved in serum-free media and incubated for 20 hours.  Cells were then 
fixed with a 20% acetone: 80% methanol solution and nuclei stained with 0.1% Hoechst 
33258 (Invitrogen; Carlsbad, CA, USA).  Two replicates were conducted for each condition 
and 12 fields (migration) or 24 fields (invasion) in each replicate were imaged and counted 
using an Olympus IX-71 inverted microscope (Olympus; Shinjuku, Tokyo, Japan), using 
InVivo Analyzer Suite (Media Cybernetics; Rockville, MD, USA).  Results are presented as 
a ratio of cells that migrated relative to cells that migrated in control conditions (cells seeded 
in serum-free media and migrating towards 10% FBS-supplemented medium). 
 
2.10 Three-Dimensional (3D) Invasion Assays 
3D invasion assays were conducted as described previously [4,14].  MDA-MB-231 and 
Hs578T cells depleted of fibulin-3 or scrambled control (2.5 x 10
4
) were seeded in a 1:1 
dilution of phenol red-free Matrigel (8.0 mg/mL; BD Biosciences; Franklin Lakes, NJ, USA) 
and culture medium on Matrigel-coated 35 mm glass-bottomed culture dishes (MatTek; 
Ashland, MA, USA).  Cultures were maintained and imaged for 5 days.  Images were taken 
with an Olympus IX-81 microscope (Olympus; Shinjuku, Tokyo, Japan), using InVivo 
Analyzer Suite (Media Cybernetics; Rockville, MD, USA).  Cell colonies were scored 
blindly as being either stellate or spheroidal. A colony is deemed to be stellate if one or more 
projections from the central sphere of a colony of cells are observed.  
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2.11 Zymography 
 Zymographic analysis was performed as described previously [15].  MDA-MB-231 
cells expressing fibulin-3 shRNA or scrambled control and SKBR3 cells expressing pFLAG 
and FLAG-KISS1R vectors (1 x 10
6
) were plated in a 6-well plate.  Subsequently, cells were 
serum starved for 24 hours and the media were collected.  Cells (2.5 x 10
5
) were serum 
starved for 24 hours and then stimulated with 100 nM KP-10 for 24 hours.  Separately, cells 
(2.5 x 10
5
) were serum starved for 24 hours and then stimulated with 500 nM EGFR inhibitor 
AG1478 (Millipore; Billerica, MA, USA) for 24 hours.  Additionally, cells (2.5 x 10
5
) serum 
starved for 24 hours were pre-treated for 30 minutes with the following drugs prior to 
stimulation with 100 nM KP-10 for 24 hours: 20 μM active ERK1/2 inhibitor UO126 
(Millipore; Billerica, MA, USA), 20 μM inactive analog UO124 (Millipore; Billerica, MA, 
USA) [16], or vehicle dimethyl sulfoxide (DMSO).  After the 24 hour stimulation period, 
media were collected.  Samples were centrifuged at 350 rcf for 5 minutes to remove cellular 
debris.  Samples were combined 1:1 with sample buffer (0.5 M Tris-HCl pH 6.8, 10% SDS, 
glycerol, 1% bromophenol blue) and 40 μL of sample was loaded onto a 10% SDS-PAGE 
separating gel copolymerized with 0.1% gelatin.  The gels were then washed in 2.5% Triton 
X-100 to remove the SDS and renature the MMP proteins.  The gels were then incubated for 
48 hours at 37 °C with gentle agitation in developing buffer (1 M Tris, 5M NaCl, 1M CaCl2 
(anhydrous), 66.67 μl  of 30% Brij-35, pH buffered to 7.4 with 6 N HCl) to allow enzymatic 
digestion of the gelatin.  Following incubation, the gels were stained with Coomassie blue, 
destained, and imaged using the VersaDoc imaging system (Bio-Rad; Hercules, CA, USA).   
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2.12 EGFR Immunoprecipitation 
 Immunoprecipitation experiments were performed as previously described [4,14].  
MDA-MB-231 and Hs578T cells expressing either fibulin-3 shRNA or scrambled control 
were cultured to 60% confluency, serum starved for 24 hours and treated with 20 ng/mL of 
EGF for 15 minutes where indicated.  Cells were washed with ice-cold PBS and lysed in 
glycerol lysis buffer (20 mM HEPES, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 2 mM 
Na3VO4, 1 mM NaF, 10% glycerol, 1% Triton X-100) containing protease inhibitors (1 
µL/mL aprotinin, 1 µL/mL leupeptin and 10 µL/mL AEBSF).  Lysates (450 µg of total 
protein) were used for immunoprecipitation studies. EGFR was immunoprecipitated from 
total lysates using anti-EGFR antibody (4 µg, Millipore; Billerica, MA, USA), incubated at 4 
°C overnight.  Immunoprecipitated proteins were then pulled-down with protein G 
Dynabeads (Life Technologies; Carlsbad, CA, USA) and resolved by Western blot analysis.  
Phosphorylated EGFR was determined using an anti-mouse antiphosphotyrosine antibody 
(PY-20, Santa Cruz; Dallas, TX, USA) at 1:1000.  Total EGFR was determined using an 
anti-EGFR antibody (1:4000, Millipore; Billerica, MA, USA).  After 1 hour incubation with 
HRP-conjugated secondary antibody, the proteins were visualized using SuperSignal West 
Dura Chemiluminescent Substrate (Thermo Scientific; Waltham, MA, USA) and a VersaDoc 
Imaging System (Bio-Rad; Hercules, CA, USA). 
 
2.13 MTT Cell Viability Assays 
 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability 
assays were conducted as per manufacturer’s instructions using a cell proliferation kit I 
(MTT) (Roche; Basel, Switzerland) to determine if depletion of endogenous fibulin-3 had 
any effect on cell viability.  MDA-MB-231 and Hs578T cells expressing fibulin-3 shRNA or 
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scrambled control were plated in triplicates (5 x 10
4
) on a 96-well plate.  MTT labeling 
reagent (10 μl) was added to each well (final concentration 0.5 mg/ml) and cells were 
incubated for 4 hours at 37°C and 5% CO2.  Subsequently, solubilization solution (10% SDS 
in 0.01 M HCl, 100 μl) was added to each well and incubated overnight at 37°C and 5% CO2.  
Absorbance was then measured at 595 nm using a Victor 3V Multi-Detection Microplate 
Reader (PerkinElmer) with a background subtraction at 750 nm. 
 
2.14 Cell Growth Assays 
 To determine if shRNA expression had any impact on cell growth rate, MDA-MB-
231 or Hs578T cells (4 x 10
5
) expressing either fibulin-3 shRNA or scrambled control were 
plated in 60 mm culture plates. Cells were trypsinized and counted using a haemocytometer 
at 24 hour intervals (24, 48 and 72 h). 
 
2.15 Statistical Analysis 
Student’s t-test, one-way analysis of variance (ANOVA) or two-way ANOVA with a 
Dunnett’s or Bonferroni’s post-hoc test were performed using GraphPad Prism 5 (GraphPad 
Software, Inc.; La Jolla, CA, USA).  Differences were considered statistically significant at 
P<0.05. 
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3.1 Plasma fibulin-3 levels increase in metastatic TNBC patients  
To date, fibulin-3 has been proposed as a plasma and effusion biomarker in malignant 
mesothelioma [1], however whether plasma fibulin-3 concentrations increase in breast cancer 
is unknown.  Thus, we investigated whether plasma fibulin-3 concentrations are increased in 
metastatic TNBC patients compared to non-metastatic TNBC patients and healthy controls 
using a fibulin-3 ELISA.  The metastatic TNBC cohort (n=7) displayed significantly higher 
plasma fibulin-3 concentrations than those of the healthy control (n=6) group (Figure 3.1).  
This study is ongoing as we acquire more samples from patients presenting at The Breast 
Care Program of St. Joseph’s Health Care London, however our data suggests that plasma 
fibulin-3 levels are increased in metastatic TNBC patients. 
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Figure 3.1. Plasma fibulin-3 levels in TNBC patients.  Fresh blood samples were taken 
from healthy patients (n=6) patients with early triple negative breast cancer (n=8) and 
metastatic triple negative breast cancer patients (n=7).  Plasma fibulin-3 levels (ng/mL) were 
measured by ELISA.  One-way ANOVA followed by Bonferroni’s multiple comparison test: 
*, P<0.05. 
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3.2 Altered EFEMP1 and KISS1 expression in invasive breast carcinoma  
Genetic alterations have been shown to influence tumor development and progression, 
and therefore identification of these alterations is important for further understanding the 
malignant process and for the development of targeted therapies [2].  To investigate if the 
genes encoding our proteins of interest were altered in cancer patients, specifically in 
invasive breast cancer patients, we used cBioPortal, an online data portal to search and 
analyze cancer genomic data sets.  Explorative analysis was performed on the fibulin-3 gene 
(EFEMP1), and the gene encoding KPs (KISS1) to determine if there was amplification, 
mRNA upregulation, and mutation of the genes.  Pathology reports for invasive breast 
carcinoma patients were also examined, however due to incompleteness, the hormone 
receptor status of the majority of these patients remains unknown.   
Cross-cancer gene alteration summaries for KISS1 and EFEMP1 were generated by 
cBioPortal.  In breast invasive carcinoma, KISS1 is amplified in 27.6% (8/29 cases; BCCRC 
Patient Xenograft British Columbia, Nature 2014) [3] and 13.6% (131/962 cases; TCGA, 
Provisional) (Figure 3.2A).  Invasive breast cancer displayed the greatest alteration 
frequency of EFEMP1 compared to other cancers (Figure 3.2B).  In breast invasive 
carcinoma, EFEMP1 is amplified 13.8% (4/29 cases; BCCRC Patient Xenograft British 
Columbia, Nature 2014) [3].   
Additionally, the Breast Invasive Carcinoma (TCGA, Provisional) dataset was used to 
generate a Kaplan–Meier overall survival curve (n=849) for both genes (Figure 3.3).  
Patients with amplified EFEMP1 (1.5%; 14/962 cases) showed no significant difference in 
survival compared to patients with unaltered EFEMP1.  Patients with amplified KISS1 
(13.6%; 131/962 cases) displayed a drastic drop (approaching statistical significance) in 
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overall survival compared to those patients without amplification of the gene.  Therefore, 
amplification of KISS1 in invasive breast carcinoma appears to influence patient survival. 
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Figure 3.2. Cross-cancer gene alteration summaries for KISS1 and EFEMP1. (A) Cross-
cancer gene alteration summary for KISS1; only top three cancers are shown. In breast 
invasive carcinoma, KISS1 is amplified in 27.6% (8/29 cases; BCCRC Patient Xenograft 
British Columbia, Nature 2014) and 13.6% (131/962 cases; TCGA, Provisional) based on Z-
score threshold of 2.0.  (B) Cross-cancer gene alteration summary for EFEMP1; only top 
three cancers are shown. In breast invasive carcinoma, EFEMP1 is amplified in 13.8% (4/29 
cases; BCCRC Patient Xenograft British Columbia, Nature 2014) based on Z-score threshold 
of 2.0. Red: gene amplification, green: gene mutation.  
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Figure 3.3. Kaplan–Meier overall survival curves comparing cases of gene alteration to 
cases without gene alteration for KISS1 and EFEMP1.  cBioPortal explorative data 
analysis was performed on both genes using the Breast Invasive Carcinoma (TCGA, 
Provisional) dataset and Kaplan–Meier overall survival curves (n=849) were generated.  P-
values were calculated by the log-rank test. 
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3.3 Fibulin-3 and KISS1R expression in breast cell lines 
 Although fibulin-3 mRNA was found to be elevated in breast cancer effusions [4], a 
role for fibulin-3 in regulating breast cancer invasion is unknown.  We first examined fibulin-
3 protein expression in mammary epithelial cells and breast cancer cell lines by western 
blotting.  We found that the expression of endogenous fibulin-3 was higher in the highly 
metastatic TNBC MDA-MB-231 cells compared to less invasive SKBR3 pFLAG control 
cells, non-invasive cells (ERα+) MCF7 cells or non-malignant MCF10A cells (Figure 3.4).  
The ERα-negative non-malignant MCF10A mammary epithelial cells are non-motile and 
non-invasive [5,6].  We have previously shown that KP-10 treatment or overexpression of 
KISS1R in the MCF10A cells stimulates EMT and increases invasiveness [7].  Additionally, 
expression of KISS1R in the ERα-negative SKBR3 cells resulted in EMT, increased cell 
invasiveness and increased extravasation in vivo [7].  Our results demonstrated that 
expression of KISS1R in the non-malignant MCF10A and the ERα-negative SKBR3 breast 
cancer cells increased the expression of endogenous fibulin-3.  This pattern of fibulin-3 
expression was also observed by immunofluorescence microscopy (Figure 3.5).  As 
previously reported [7], KISS1R protein expression was high in the highly invasive breast 
cells (SKBR3 FLAG-KISS1R, MDA-MB-231) compared with the less invasive and non-
invasive cell lines.  Hence, our results indicate that fibulin-3 may play a role in breast cancer 
cell invasion, and that KISS1R may regulate the expression of fibulin-3. 
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Figure 3.4. Expression of fibulin-3 and KISS1R in breast cell lines. (A) Representative 
western blots and (B) densitometric analysis of endogenous fibulin-3 (n=3) and KISS1R 
(n=4) in various breast cell lines. One-way ANOVA followed by Dunnett’s post hoc test: *, 
P<0.05 compared to MCF10A pFLAG.  β-actin, loading control.  Columns represent protein 
expression ± standard error of the mean (SEM). 
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Figure 3.5. Endogenous fibulin-3 expression in breast cells. Representative confocal 
micrographs of various breast cell lines (n=4) immunostained with anti-fibulin-3 (rabbit) 
followed by AlexaFluor 488 (green). Nuclei stained with Hoechst 33258. Scale bar = 20 μm.   
 
MCF7 MDA-MB-231 Hs578T 
SKBR3 pFLAG SKBR3 FLAG-KISS1R 
MCF10A pFLAG MCF10A FLAG-KISS1R 
68 
 
3.4 Kisspeptin-10 signaling stimulates fibulin-3 expression and secretion in ERα-
negative breast cancer cells 
Next, to investigate if activation of KISS1R promotes fibulin-3 expression we treated 
ERα-negative breast cancer cells with 100 nM kisspeptin-10, as determined by previous dose 
response studies [7,8], and examined fibulin-3 protein expression in cell lysates, as well as 
concentrated conditioned media by western blotting.  Treatment of breast cancer cells with 
KP-10 (100 nM, 72 hr), significantly increased fibulin-3 protein levels compared to 
unstimulated cells, as determined by western blot analysis (Figure 3.6).  Additionally, since 
fibulin-3 is a secreted protein, we also examined the ability of KP-10 to stimulate fibulin-3 
secretion in ERα-negative breast cancer cells.  KP-10 treatment also increased fibulin-3 
protein levels in conditioned media (Figure 3.7).  Therefore, KISS1R signaling regulates 
fibulin-3 expression and secretion in ERα-negative breast cancer cells. 
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Figure 3.6. KP-10 stimulates the expression of fibulin-3 in ERα-negative breast cancer 
cells. (A) Representative western blot showing expression levels of fibulin-3 in ER-α 
negative breast cells unstimulated or after 100 nM kisspeptin-10 in complete media treatment 
for 72 hours. (B) Densitometric analysis of fibulin-3 (n=3) expression levels following 
kisspeptin-10 stimulation; β-actin, loading control. Student’s t-test: *, P<0.05.  Columns 
represent protein expression ± SEM. 
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Figure 3.7. KP-10 stimulates the secretion of fibulin-3 in ERα-negative breast cancer 
cells. (A) Representative western blot showing fibulin-3 in conditioned media from ER-α 
negative breast cells unstimulated or after 100 nM kisspeptin-10 in serum free media 
treatment for 24 hours. (B) Densitometric analysis of fibulin-3 (n=3) levels following 
kisspeptin-10 stimulation. Student’s t-test: *, P<0.05.  Columns represent protein expression 
± SEM. 
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3.5  β-arrestins regulate the expression of fibulin-3 protein in TNBC cells 
We have previously shown that β-arrestin2 regulates KP-10 induced EGFR activation 
and cell invasion in TNBC cells [8].  Thus, we determined whether changes in β-arrestin 
protein levels altered fibulin-3 expression levels by western blotting.  We observed that 
depletion of endogenous β-arrestin1 or β-arrestin2 in MDA-MB-231 cells decreased the 
expression of fibulin-3 protein levels, compared to cells expressing scrambled controls 
(Figure 3.8).  This data suggests that β-arrestins also regulate the expression of fibulin-3 in 
TNBC cells. 
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Figure 3.8. β-arrestins regulate the expression of fibulin-3 protein in TNBC cells.  (A) 
Representative western blot and densitometric analysis of (B) β-arrestin 1 (n=8), and β-
arrestin 2 (n=8) and (C) fibulin-3 (n=3) in MDA-MB-231 cells expressing β-arrestin1 or β-
arrestin2 shRNA or scrambled control; β-actin, loading control. One-way ANOVA followed 
by Dunnett’s multiple comparison test: *, P<0.05 compared to MDA-MB-231 scrambled.  
Columns represent protein expression ± SEM. 
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3.6 Depletion of fibulin-3 diminishes TNBC cell migration 
Metastasis is dependent on the ability of cancer cells to invade the surounding tissue 
and the cell’s ability to migrate away from the primary tumor [9,10].  To examine a potential 
mechanism by which fibulin-3 regulates TNBC cell migration, endogenous fibulin-3 was 
depleted in the invasive TNBC MDA-MB-231 and Hs578T cell lines using lentivirus-
delivered shRNA and knockdown was verified by western blot (Figure 3.9A, B).  Depletion 
of fibulin-3 had no effect on cell viability (Figure 3.9C).  Additionally, we examined if 
secretion of fibulin-3 was also diminished in MDA-MB-231 and Hs578T cells stably 
expressing fibulin-3 shRNA, and observed that it was significantly depleted (Figure 3.10).  
To assess a role of fibulin-3 in TNBC cell migration, we first used scratch motility assays, as 
previously conducted [7,8,11].  Data showed a significant decrease in the distance migrated 
by cells depleted of endogenous fibulin-3 compared to the scrambled controls (Figure 3.11).  
Cell migration was also measured using transwell chamber migration assays, as previously 
described [7,8,11,12].  MDA-MB-231 cells depleted of fibulin-3 or scrambled control were 
seeded in serum-free media or serum-free media containing 100 nM KP-10 and allowed to 
migrate across the transwell migration membrane towards serum-free or FBS-supplemented 
media for 20 hours.  The depletion of fibulin-3 significantly decreased the ability of cells to 
migrate across the membrane under basal and KP-10 stimulated conditions (Figure 3.12).  
Additionally, cell growth assays demonstrated that there were no differences in cell 
proliferation, indicating that the observed differences in scratch closure and transwell 
migration assays were a result of changes in cell migration and not differences in cell 
proliferation (Figure 3.13).  Therefore, these results indicate that fibulin-3 regulates TNBC 
cell migration. 
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Figure 3.9.  Fibulin-3 knockdown in TNBC cells using shRNA. Representative western 
blot and densitometric analysis of fibulin-3 (n=3) in (A) MDA-MB-231 cells stably 
expressing fibulin-3 shRNA or scrambled control and (B)  Hs578T cells stably expressing 
fibulin-3 shRNA  or scrambled control; β-actin, loading control. One-way ANOVA followed 
by Dunnett’s multiple comparison test: *, P<0.05 compared to scrambled.  Columns 
represent protein expression ± SEM.  (C) MDA-MB-231 and Hs578T cells expressing 
fibulin-3 shRNA or scrambled control were cultured in 96-well plates and cell viability was 
determined by MTT assay (n=3).  Columns represent absorbance measured at 550 nm minus 
background reading at 700 nm ± SEM. 
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Figure 3.10.  Fibulin-3 knockdown in TNBC cells decreases fibulin-3 secretion. 
Representative western blot and densitometric analysis of fibulin-3 (n=3) in conditioned 
media from (A) MDA-MB-231 cells stably expressing fibulin-3 shRNA or scrambled control 
and (B)  Hs578T cells stably expressing fibulin-3 shRNA  or scrambled control.  Student’s t-
test: *, P<0.05.  Columns represent protein expression ± SEM. 
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Figure 3.11.  Depletion of fibulin-3 inhibits TNBC cell motility.  Cell motility measured 
using the scratch assay (n=3) in both MDA-MB-231 and Hs578T cells depleted of 
endogenous fibulin-3 over an 18 hour and 15 hour period, respectively.  Two-way ANOVA 
followed by Bonferroni’s multiple comparison test: a, P < 0.05 for Fibulin-3 shRNA 
construct #1 vs. scrambled control; b, P <0.05 Fibulin-3 shRNA construct #2 vs. scrambled 
control. Scale bar = 50 μm.   
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Figure 3.12. Depletion of fibulin-3 inhibits MDA-MB-231 cell migration in transwell 
chamber migration assay. MDA-MB-231 cells depleted of fibulin-3 display decreased 
migration towards 10% fetal bovine serum (FBS) under basal and kisspeptin-10 stimulated 
conditions (n=3). One-way ANOVA followed by Bonferroni’s multiple comparison test: a, 
P<0.05 for significance difference vs scrambled control non-stimulated; b, P<0.05 for 
significance difference vs scrambled control 100 nM kisspeptin-10.  Columns represent cells 
migrated to lower chamber ± SEM. 
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Figure 3.13. Depletion of endogenous fibulin-3 does not affect cell growth. MDA-MB-
231 or Hs578T cells (4 x 10
5
) expressing fibulin-3 shRNA or scrambled control were 
cultured for 72 hours and counted at 24 hour intervals (n=3). 
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3.7 Depletion of fibulin-3 inhibits TNBC cell invasion.  
Matrigel is a reconstituted extracellular matrix that mimics the in vivo tumor 
microenvironment, enabling cells to grow in 3D [7,8,11,13].  To assess a role for fibulin-3 in 
TNBC cell invasion, a 3D Matrigel invasion assay was conducted, as previously described 
[7,8,11,12].  MDA-MB-231 and Hs578T cells depleted of fibulin-3 had a diminished ability 
to form invasive, or stellate, colonies when cultured in Matrigel (5 days) compared to 
scrambled control cells (Figure 3.14, 3.15).  The viability of colonies was verified by 
examining cell nuclei integrity using Hoechst staining.  We also assessed the role of fibulin-3 
in cell invasion using transwell Matrigel invasion assays, as previously conducted 
[7,8,11,12].  Cells were layered on a 1 in 10 dilution of Matrigel in serum-free media or 
serum-free media containing 100 nM KP-10 and allowed to migrate across the transwell 
migration membrane towards serum-free or FBS-supplemented media for 20 hours. The 
depletion of fibulin-3 significantly decreased the ability of cells to invade across the 
membrane in unstimulated and KP-10 stimulated conditions (Figure 3.16).  These findings 
demonstrate that fibulin-3 regulates the invasive ability of TNBC cells. 
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Figure 3.14. Fibulin-3 knockdown inhibits MDA-MB-231 TNBC cell invasion in three-
dimensional Matrigel assay.  MDA-MB-231 cells expressing fibulin-3 shRNA or 
scrambled controls were suspended in Matrigel for 5 days and the number of invasive stellate 
structures were counted (n=3). Cells were fixed and nuclei were stained with Hoechst 33258 
on day 5.  Representative images shown. White arrows: stellate invasive structures; scale bar 
= 50 μm. Two-way ANOVA followed by Bonferroni’s multiple comparison test: a, P<0.05 
scrambled control vs fibulin-3 shRNA construct #1; b, P<0.05 scrambled control vs fibulin-3 
shRNA construct #2. 
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Figure 3.15. Fibulin-3 knockdown inhibits Hs578T TNBC cell invasion in three-
dimensional Matrigel assay.  Hs578T cells expressing fibulin-3 shRNA or scrambled 
controls were suspended in Matrigel for 5 days and the number of invasive stellate structures 
were counted (n=3). Cells were fixed and nuclei were stained with Hoechst 33258 on day 5.  
Representative images shown. White arrows: stellate invasive structures;  scale bar = 50 μm. 
Two-way ANOVA followed by Bonferroni’s multiple comparison test: a, P<0.05 scrambled 
control vs fibulin-3 shRNA construct #1; b, P<0.05 scrambled control vs fibulin-3 shRNA 
construct #2. 
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Figure 3.16. Depletion of fibulin-3 inhibits TNBC cell invasion in transwell chamber 
Matrigel invasion assay. MDA-MB-231 and Hs578T cells depleted of fibulin-3 display 
decreased invasion towards 10% fetal bovine serum (FBS) under basal conditions and 
inhibition of kisspeptin-10 induced cell invasion (n=3). One-way ANOVA followed by 
Bonferroni’s multiple comparison test: a, P<0.05 for significance difference vs scrambled 
control non-stimulated; b, P<0.05 for significance difference vs scrambled control 100 nM 
kisspeptin-10.  Columns represent cells invaded to lower chamber ± SEM. 
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3.8 Depletion of fibulin-3 decreases MAPK signaling and MMP-9 expression and 
activity 
Fibulin-3 has been shown to regulate the phosphorylation of ERK and AKT 
downstream of EGFR in pancreatic cancer cells [14].  To initially examine potential 
mechanisms by which fibulin-3 regulates TNBC cell invasion, we investigated the 
phosphorylation status of ERK and AKT.  Upon depletion of fibulin-3 in the TNBC cell 
lines, we observed decreased phosphorylation of ERK compared to scrambled controls 
(Figure 3.17).  However, there was no significant change in AKT phosphorylation (Figure 
3.17). 
Fibulin-3 has also been shown to regulate MMP-9 expression and activity in lung 
cancer and malignant glioma [15,16].  Therefore to determine whether fibulin-3 regulates 
TNBC cell invasion via MMP-9, we examined the effect of fibulin-3 depletion on MMP-9 
expression and activity by western blotting and zymography, respectively.  MMP-9 
expression significantly decreased upon depletion of fibulin-3 in both the MDA-MB-231 and 
Hs578T cell lines compared to scrambled controls (Figure 3.18A).  Additionally, 
zymography demonstrated that MMP-9 activity was diminshed in the MDA-MB-231 cells 
depleted of fibulin-3 (Figure 3.18B).     This data suggests that fibulin-3 may regulate TNBC 
cell invasion via an ERK and MMP-9 dependent pathway. 
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Figure 3.17.  Depletion of fibulin-3 in TNBC cells reduces the phosphorylation of 
downstream signaling molecules. Representative western blot and densitometric analysis of 
pERK (n=3) and pAKT (n=3) in (A) MDA-MB-231 cells or (B) Hs578T cells expressing 
fibulin-3 shRNA or scrambled control; β-actin, loading control. One-way ANOVA followed 
by Dunnett’s multiple comparison test: *, P<0.05 compared to scrambled.  Columns 
represent protein expression ± SEM. 
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Figure 3.18.  Depletion of fibulin-3 in TNBC cells decreases the expression and activity 
of MMP-9. (A) Representative western blot and densitometric analysis of MMP-9 (n=3) in 
MDA-MB-231 and Hs578T cells expressing fibulin-3 shRNA or scrambled contro; β-actin, 
loading control. One-way ANOVA followed by Dunnett’s multiple comparison test: *, 
P<0.05 compared to scrambled.  Columns represent protein expression ± SEM.  (B) 
Depletion of fibulin-3 in MDA-MB-231 cells reduces MMP-9 activity (n=3) shown by 
zymography.   
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3.9 Depletion of fibulin-3 inhibits kisspeptin-10-induced MMP-9 secretion and activity 
 Our lab has previously shown that KP-10 stimulates MMP-9 secretion and activity in 
MDA-MB-231 cells [4].  Thus, we examined MMP-9 activity in the SKBR3 breast cancer 
cells overexpressing KISS1R, and observed that KISS1R overexpression also increased 
MMP-9 secretion and activity (Figure 3.19A). We also sought to determine if fibulin-3 
regulates KP-10 induced MMP-9 activity by conducting zymography with the MDA-MB-
231 cells depleted of fibulin-3.  Zymography revealed that depletion of fibulin-3 inhibited the 
KP-10 induced secretion and activity of MMP-9 (Figure 3.19B).  Therefore, KISS1R 
signaling stimulates MMP-9 secretion and activity via a fibulin-3 dependent mechanism. 
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Figure 3.19. Depletion of fibulin-3 inhibits KP-10-induced MMP-9 secretion and 
actvity.  (A) Overexpression of KISS1R in SKBR3 breast cancer cells increases MMP-9 
secretion and activity (n=3), shown by zymography.  (B) Depletion of fibulin-3 in MDA-
MB-231 cells blocks basal and KP-10 stimulated MMP-9 secretion and activity (n=4).   
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3.10 Inhibition of ERK signaling further diminshes MMP-9 secretion and acitivty 
  MMP-9 has been shown to regulate invasion downstream of ERK signaling in 
MCF7 and MDA-MB-231 breast cancer cells [17].  Additionally, since the western blot 
results revealed that phosphorylation of ERK is diminished in fibulin-3 knockdown cells, we 
next examined the effect of inhibiting ERK signaling on MMP-9 secretion and activity.  
MDA-MB-231 cells stably expressing fibulin-3 shRNA or scrambled control displayed a 
decrease in basal and KP-10 induced MMP-9 secretion and activity upon pretreatment with 
ERK1/2 inhibitor, UO126 (Figure 3.20). In contrast, MMP-9 secretion and activity did not 
change in cells treated with the inactive analog, UO124, compared to vehicle control (Figure 
3.20).  This data demonstrates that KP-10 induced MMP-9 secretion and activity is 
dependent on ERK signaling, and this may occur downstream of fibulin-3. 
 EGFR signaling has been shown to regulate MMP-9 via an ERK-dependent pathway 
in SKBR3 breast cancer cells [18].  Thus, to determine if the involvement of fibulin-3 in  
MMP-9 secretion and activity is EGFR dependent, we repeated zymography with MDA-MB-
231 cells stably expressing fibulin-3 shRNA or scrambled control stimulated with EGFR 
inhibitor, AG1478.  We found that AG1478 treatment appeared to slightly decrease MMP-9 
activity in the scrambled control, however there was no noticeable further decrease in the 
fibulin-3 knockdown cells (Figure 3.21).  Therefore, this suggests that fibulin-3 regulates 
MMP-9 secretion and activity in TNBC cells, and that this may occur independently of 
EGFR activity. 
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Figure 3.20. Inhibition of ERK signaling blocks basal and KP-10-induced MMP-9 
secretion and actvity.  MDA-MB-231 cells stably expressing fibulin-3 shRNA or scrambled 
control were pre-treated for 30 minutes with the following drugs prior to stimulation with 
100 nM KP-10 for 24 hours: 20 μM active ERK1/2 inhibitor, UO126  or 20 μM inactive 
analog, UO124.   Representative zymograph of three independent experiments is shown. 
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Figure 3.21. EGFR inhibition decreasesMMP-9 secretion and actvity in scrambled 
control but not in fibulin-3 depleted cells.  MDA-MB-231 cells stably expressing fibulin-3 
shRNA or scrambled control were treated with 500 nM EGFR inhibitor, AG1478.   
Representative zymograph of three independent experiments is shown. 
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3.11 Depletion of fibulin-3 decreases EGFR phosphorylation in TNBC cells 
 Fibulin-3 has been shown to compete with EGF for binding and activation of EGFR 
in pancreatic cancer cells [14], however whether fibulin-3 activates EGFR in breast cancer 
cells remains unknown.  Therefore, to assess whether fibulin-3 activates EGFR in TNBC 
cells, lysates from unstimulated and EGF treated MDA-MB-231 and Hs578T cells stably 
expressing fibulin-3 shRNA or scrambled control were examined for phosphorylated 
endogenous EGFR by western blotting.  We observed that both MDA-MB-231 and Hs578T 
cells depleted of fibulin-3 displayed significantly less phosphorylation of EGFR (Figure 
3.22).  These results indicate that fibulin-3 regulates EGFR phosphorylation in TNBC cells. 
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Figure 3.22. Depletion of fibulin-3 decreases EGFR phosphorylation in TNBC cells.  (A) 
MDA-MB-231 (n=3) and (B) Hs578T (n=4) cells stably expressing fibulin-3 shRNA or 
scrambled control treated with 20 ng/mL EGF for 0 or 15 minutes.  EGFR was 
imunopreciptated and blots were probed with phosphorylated and total EGFR. Quantification 
of phosphorylated EGFR expression normalized to EGFR pulled down.  One-way ANOVA 
followed by Bonferroni’s multiple comparison test: a, P<0.05 for significance difference vs 
scrambled control non-stimulated; b, P<0.05 for significance difference vs scrambled control 
20 ng/mL EGF.  Columns represent protein expression ± SEM. 
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4.1 Summary of Novel Findings and Conclusions 
Objective #1:  To determine if plasma fibulin-3 levels are increased in TNBC patients 
compared to healthy controls. 
 cBioPortal data analysis of the TCGA database revealed that KISS1 gene had the 
highest amplification frequency in invasive breast carcinoma and patients with alteration 
displayed  a drastic decrease in survival.  However, EFEMP1 gene was altered only 1.5% in 
invasive breast carcinoma patients. Despite the apparent lack of amplification, plasma 
fibulin-3 concentrations are elevated in metastatic TNBC patients compared to non-
metastatic TNBC and healthy patients.  These results indicate that fibulin-3 may be a marker 
of metastasis in TNBC patients. 
 
Objective #2:  To determine if fibulin-3 positively regulates KISS1R-induced TNBC cell 
invasion, and the underlying mechanism(s). 
 We show for the first time that depletion of fibulin-3 resulted in decreased basal and 
KP-10 stimulated TNBC cell migration and invasion, two important processes involved in 
cancer metastasis.  We also found that fibulin-3 depletion resulted in decreased 
phosphorylation of ERK and reduced expression and activity of MMP-9.  Additionally, KP-
10-induced MMP-9 activity was further reduced by ERK inhibition.  Thus, our results 
suggest that fibulin-3 promotes TNBC cell invasion downstream of KISS1R signaling by 
regulating ERK and MMP-9 secretion and activity (Figure 4.1). 
 
Objective #3:  To determine if fibulin-3 regulates EGFR phosphorylation in TNBC cells.
 Depletion of fibulin-3 in TNBC cells resulted in decreased EGFR phosphorylation.  
These results demonstrate that fibulin-3 may regulate EGFR activation in TNBC cells. 
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4.2 Contributions of Research to Current State of Knowledge  
 GPCR signaling has been shown to be an important mediator of intracellular 
signaling in both physiological and pathological conditions [1,2].  GPCR signaling involves 
complex G-protein independent and G-protein dependent downstream signaling pathways.  
In addition, GPCRs have been shown to transactivate receptor tyrosine kinases (RTKs) by 
stimulating tyrosine phosphorylation through a variety of mechanisms [3].  GPCR 
transactivation of the RTK, EGFR, has been demonstrated in lung, ovarian, colon, prostate 
and breast cancer [4].  Overexpression of EGFR in many cancers has been correlated with 
increased cell survival, growth and invasion [5,6].  Specifically, TNBC, which currently 
lacks effective targeted therapies, overexpresses EGFR [7].  However, clinical therapies 
designed to inhibit EGFR signaling by targeting the extracellular domain or the tyrosine 
kinase domain have been ineffective due to acquired drug resistance [8].  Our lab has 
mechanistically shown that KISS1R regulates TNBC cell invasion via β-arrestin2 and 
IQGAP1, and that these proteins are required for KISS1R transactivation of EGFR [9,10].  
Therefore, further elucidating the mechanism by which KISS1R regulates EGFR activity and 
cell invasion in TNBC may identify novel therapeutic targets for use in combination therapy.  
The tumor microenvironment has been implicated in many of the processes 
associated with the progression of cancer, including initial carcinogenesis, metastasis and 
drug resistance [11].  Therefore, components of the tumor microenvironment are emerging as 
potential preventative and therapeutic targets in the treatment of cancer [12].  Specifically, 
proteins secreted by cancer cells into the tumor microenvironment may represent important 
targets, as their expression profiles in cancers have the potential to aid in earlier diagnosis 
and the assessment and prevention of cancer progression [13].  Additionally, ECM proteins 
98 
 
have an influential role in tumor progression and metastasis and targeted ECM inhibitors are 
worth considering as anti-metastatic therapies [14].   
 
Fibulin-3 Expression in TNBC 
 Fibulin-3 expression has been examined in several cancers, including breast cancer, 
however whether fibulin-3 expression increases in TNBC remains unknown.  Our results 
demonstrated that compared to EFEMP1, KISS1 is amplified more in invasive breast cancer, 
compared to other cancers.  Gene amplification is a common genetic alteration in cancer that 
is useful for prognostic and diagnostic purposes [15].  Additionally, invasive breast 
carcinoma patients with amplified KISS1 displayed a drastic decrease in overall survival 
compared to patients without alterations in the gene.  Whether plasma kisspeptin levels are 
increased in TNBC patients is being examined as part of another ongoing study in our lab.  
We found that plasma fibulin-3 concentrations in metastatic TNBC patients are elevated 
compared to healthy controls.  We next examined fibulin-3 protein levels and found that 
fibulin-3 is higher in invasive cells compared to weakly invasive or non-malignant cells.   
To date, one study indicates that fibulin-3 is overexpressed in breast cancer effusions 
[16] whereas another study suggests that fibulin-3 may be down-regulated in primary breast 
tumors [17].  These inconsistent reports could be the result of numerous factors, such as 
differences in the origin of the sample, breast cancer subtype and advancement of the disease.  
Additionally, a recent study reported that fibulin-3 mRNA is decreased in primary breast 
tumors compared to normal breast [16].  Using the Oncomine database, the authors 
demonstrated that fibulin-3 mRNA decreases with increasing staging of breast cancer and  
that low fibulin-3 expression correlated with poor patient survival [16].  They suggested that 
decreased fibulin-3 expression is a result of epigenetic silencing through promoter 
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methylation [16].  Moreover, using MCF10A and MDA-MB-231 cells, the study 
demonstrated that fibulin-3 mRNA decreased in isogenic lines that  had greater invasive 
capabilities [16].  One possible reason for the difference between this study and our 
observations is that the correlation between mRNA and protein expression does not always 
go hand in hand [17].  Translation of mRNA in cancer has been shown to be dysregulated 
through changes in translational efficiency, availability of translational machinery and 
activation of translation through aberrantly activated signaling pathways [18].  Additionally, 
since proteins are the final product of transcription and translation and the main effectors of 
signaling cascades, they may better reflect gene function [17].  Thus, our novel data 
revealing increased fiublin-3 protein in the circulation of metastatic TNBC patients may 
accurately represent fibulin-3 expression in TNBC. 
 
Fibulin-3 in TNBC Cell Migration and Invasion  
 KISS1R stimulates the secretion of the GnRH hormone [19,20], however we have 
shown for the first time, that KISS1R signaling is capable of regulating the expression and 
secretion of the ECM protein, fibulin-3.  Our results demonstrated that kisspeptin-10 
stimulation significantly increased the expression and secretion of fibulin-3 in the ERα-
negative SKBR3 breast cancer overexpressing KISS1R and pFLAG controls.  Thus, our 
results support that fibulin-3 may be a downstream effector of KISS1R signaling, and that 
KISS1R signaling may influence components of the tumor microenvironment. 
ECM remodeling, migration and invasion are all integral to the process of cancer cell 
metastasis [21].  For our study, we used two human TNBC cell lines, MDA-MB-231 and 
Hs578T.  Our lab has previously shown that kisspeptin-10 stimulation of these cells promotes 
migration and invasion [9,10].  Our study extended these findings by demonstrating that 
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fibulin-3 depletion reduced TNBC cell migration as assessed by scratch and transwell 
migration assays, thereby supporting a role for fibulin-3 in TNBC cell migration.  Moreover, 
fibulin-3 depletion inhibited both basal and kisspeptin-10 stimulated migration assessed in 
the transwell chamber migration assay, therefore suggesting that fibulin-3 may positively 
regulate kisspeptin-10-induced TNBC cell migration.   
 Our findings also supported a role for fibulin-3 in TNBC cell invasion by 
demonstrating that depletion of fibulin-3 resulted in decreased invasion of MDA-MB-231 
and Hs578T cells in the 3D Matrigel invasion assays and transwell Matrigel invasion assays.  
In addition, fibulin-3 depletion inhibited both basal and kisspeptin-10 stimulated invasion in 
the transwell Matrigel invasion assays.  Tian and colleagues reported that overexpression of 
fibulin-3 inhibits TGF-β signaling, EMT, invasion and metastasis in vivo [16].  However, the 
TGF-β pathway has been reported to be both tumor suppressive and tumor promoting in 
breast cancer [22,23,24].  The effects of TGF-β are dependent on the cell type, differentiation 
and microenvironment [24].  Additionally, mouse models have demonstrated that mammary 
epithelial cell specific expression of activated TGF-β ligand or expression of a constitutively 
active type I TGF-β receptor results in increased lung metastases in vivo [25,26].  It has been 
proposed that TGF-β signaling could suppress primary tumor growth while promoting 
metastases through EMT in a subpopulation of breast cancer cells [24].  Interestingly, 
treatment of TNBC mouse models with TGF-β neutralizing antibodies or receptor kinase 
inhibitors prevents the development of lung and bone metastases [27].  Therefore, perhaps 
the effects of fibulin-3 on TGF-β signaling and metastasis differ in TNBC patients. 
MMP-9 has been shown to mediate the pro-invasive role of fibulin-3 in malignant 
glioma [28].   Similarly, we observed decreased expression and activity of MMP-9 in TNBC 
cells depleted of fibulin-3.  Our lab has previously demonstrated that kisspeptin-10 stimulates 
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MMP-9 secretion and activity in MDA-MB-231 cells [9].  Our current results also 
demonstrated that KISS1R overexpression in the SKBR3 breast cancer cells increases MMP-
9 secretion and activity, thereby supporting the previous study.  Additionally, our results 
demonstrated that kisspeptin-10 induced stimulation of MMP-9 is dependent on fibulin-3.  
Interestingly, ERK signaling has been reported to regulate MMP-9 mediated invasion in 
breast cancer cells [29].  We observed significant decreases in ERK phosphorylation in 
TNBC cells depleted of fibulin-3, and ERK inhibition decreased both scrambled and depleted 
fibulin-3 TNBC cell basal and kisspeptin-10-induced MMP-9 secretion and activity.  Despite 
observing a significant decrease in ERK phosphorylation in the MDA-MB-231 cells depleted 
of fibulin-3, a high level of phosphorylation remained that can be explained by previous 
reports that MDA-MB-231 cells carry an activated kristen rat sarcoma viral oncogene 
homolog (K-ras) due to a mutation in the KRAS gene, resulting in high basal ERK 
phosphorylation [30,31].  Thus, our studies uncover a mechanism by which kisspeptin-10-
induced MMP-9 activity and TNBC cell invasion are dependent on fibulin-3 and ERK 
signaling. 
 
Fibulin-3 regulates EGFR Activation in TNBC  
 Fibulin-3 has been shown to compete with EGF for binding and activation of EGFR 
in pancreatic cancer cells [32].  Notably, EGFR is overexpressed in TNBC [7], and 
contributes to increased cell survival, proliferation and invasion [5,6].  Our results revealed 
that fibulin-3 depletion in the TNBC cells significantly reduced EGFR phosphorylation and 
therefore activation.  Thus, our results are the first to demonstrate that fibulin-3 is required 
for EGFR phosphorylation in TNBC.  Additionally, KISS1R signaling has been reported to 
lead to β-arrestin2 dependent ERK activation [33,34].  Our lab has previously shown that 
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kisspeptin-10 stimulation leads to β-arrestin2 dependent transactivation of EGFR, a well-
known ERK activator [9,35].  Our current results demonstrated that depletion of endogenous 
β-arrestin1 or 2 significantly decreases fibulin-3 protein expression in the MDA-MB-231 
cells.  For that reason, KISS1R may transactivate EGFR in a β-arrestin2 and fibulin-3 
dependent mechanism, however, this needs to be investigated further. 
 
4.3 Limitations and Future Directions 
 Our research involving patient plasma has revealed that fibulin-3 concentrations are 
elevated in metastatic TNBC.  The sample size for each group is currently being increased as 
we collect more patient plasma samples and evaluate the fibulin-3 concentration by ELISA.  
Currently we are only evaluating secreted fibulin-3 levels in the circulation and stability of 
fibulin-3 in the blood is unknown.  Therefore, it may be of interest to evaluate fibulin-3 
mRNA and protein expression (the latter by immunohistochemistry) in TNBC primary 
tumors compared to adjacent normal tissue and these studies are underway.  Secondly, using 
an in vivo orthotopic xenograft mouse model we could examine the effects of fibulin-3 
depletion on metastasis.  The orthotopic xenograft mouse model has been shown to 
accurately resemble breast cancer gene expression profiles observed in patient primary breast 
tumors, thus providing an accurate model to assess the role of fibulin-3 in human TNBC 
metastasis [36].  Orthotopic xenograft mouse models could be established in 
immunodeficient mice by subcutaneous injection of MDA-MB-231 cells depleted of fibulin-
3 and number and size of lung metastases could be evaluated.   These studies will be 
conducted in the near future.   
Our results demonstrated that KISS1R signaling regulates fibulin-3 expression, 
however the mechanism(s) by which this is occurring is currently unknown.  To determine 
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whether this is occurring transcriptionally fibulin-3 mRNA can be measured in KP-10-
induced cells by real-time PCR. Alternately, fibulin-3 protein stability may be increased and 
this can be assessed by examining the rate of protein degradation through differences in half-
life [37].  We also demonstrated that β-arrestins regulate the expression of fibulin-3.  β-
arrestins function as substrates and adaptors for ubiquination [38].  Additionally, β-arrestins 
can escort E3 ubiquitin ligases to mediate ubiquitination of various proteins, including 
transmembrane receptors, ion channels, kinases and other regulatory proteins such as the 
tumor suppressor p53 [38].  Thus, β-arrestins could be regulating fibulin-3 protein stability 
downstream of KISS1R signaling and this requires further investigation. 
Additionally, the data supporting a role for fibulin-3 in TNBC could be strengthened 
by the use of a gain of function model, by performing the migration and invasion assays in 
TNBC cells overexpressing fibulin-3.  Our results also demonstrated that fibulin-3 positively 
regulates MMP-9 secretion and activity in TNBC, specifically MDA-MB-231 cells.  One 
limitation of the use of zymography to establish the effect of EGFR inhibition in MDA-MB-
231 cells depleted of fibulin-3 is that MMP-9 activity was already severely diminished in the 
knockdown cells, making it difficult to observe any further decrease and confidently 
conclude that fibulin-3 stimulation of MMP-9 is EGFR independent.  Therefore, to improve 
our confidence regarding the effect of EGFR inhibition on fibulin-3, it would be greatly 
beneficial to repeat this experiment by treating cells overexpressing fibulin-3 with the EGFR 
inhibitor, AG1478, and examining MMP-9 activity by zymography.  Fibulin-3 has also been 
shown to mediate invasion through MMP-2 expression and activity [28].  MDA-MB-231 
cells have been shown to express MMP-9, but lack MMP-2, conversely Hs578T cells have 
high levels of MMP-2 and lack MMP-9 [39].  Therefore, to further our findings, the effect of 
fibulin-3 depletion in Hs578T cells on MMP-2 expression and activity could also be 
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examined by zymography.  These studies would allow us to determine a role for MMP-2 in 
TNBC cell invasion, in addition to MMP-9.     
 Our results demonstrated that EGFR phosphorylation was diminished in TNBC cells 
depleted of fibulin-3.  We could strengthen these results by also treating MDA-MB-231 cells 
with exogenous purified fibulin-3 and examining the phosphorylation of EGFR.  The ability 
of KISS1R to transactivate EGFR via fibulin-3 remains unknown.  Therefore transactivation 
experiments will be conducted as previously described [9,10], by stimulating TNBC cells 
depleted of fibulin-3 with kisspeptin-10 and examining phosphorylation of EGFR.  Total 
EGFR expression also appeared to decrease in TNBC cells depleted of fibulin-3.  Therefore, 
further knowledge regarding EGFR regulation could be obtained by examining total EGFR 
mRNA and protein expression in the TNBC cells depleted of fibulin-3.  Depending on the 
results acquired, a potential transcriptional or translational mechanism could be further 
investigated to determine the mechanism by which fibulin-3 may be regulating EGFR in 
TNBC cells.   
 
4.4 Conclusions 
 Our results demonstrate for the first time that KISS1R signaling stimulates fibulin-3 
expression and secretion and that fibulin-3 positively regulates EGFR activation and 
KISS1R-induced cell invasion in TNBC (Figure 4.1).  Additionally, this KISS1R-induced 
cell invasion occurs via fibulin-3 dependent stimulation of MMP-9 secretion and activity in 
an ERK-dependent manner.  Patient data demonstrates that plasma fibulin-3 concentrations 
may be a useful marker of metastasis in TNBC.  Thus, this study has identified fibulin-3 as a 
novel potential therapeutic target for prevention of human TNBC cell invasion and 
metastasis. 
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Figure 4.1. Our proposed model for fibulin-3 in regulating TNBC cell invasion.  
Previous studies in our lab have demonstrated that KISS1R activates EGFR via β-arrestin2 
and that β-arrestin2 is required for KISS1R-induced MMP-9 activity and invasion in TNBC 
cells (black dashed arrows).  Our current results (red arrows) demonstrate that KISS1R 
signaling stimulates fibulin-3 expression and secretion in TNBC cells.  Additionally, we have 
found that β-arrestin2 also regulates fibulin-3 expression.  We demonstrated that fibulin-3 
regulates KISS1R-induced TNBC cell invasion via ERK and MMP-9 and regulates EGFR 
phosphorylation.  Thus the ECM protein, fibulin-3 is a signaling partner for KISS1R in 
regulating TNBC cell invasion.  
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